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Abstract 
 
The protein IspH, (E)-1-hydroxy-2-methyl-but-2-enyl 4-diphosphate reductase, is an 
essential enzyme in isoprenoid biosynthesis and an important drug/herbicide target. The 
main research in this work investigated the structures and functions of IspHs from 
various organisms.  
Using a sequence similarity network we found that some IspHs form “Rosetta-stone” 
fusion proteins with either the ribosomal protein S1 (RPS1), or a UbiA (4-
hydroxybenzoate octaprenyltransferase)-like protein. These fusion proteins are all from 
obligately anaerobic bacteria. A catalytically active IspH-RPS1 was expressed and 
characterized. The existance of these fusion proteins is indicative of possible secondary 
roles of the enzyme IspH, perhaps being involved in O2 sensing and regulation.  
Using crystallographic and bioinformatics results we show that IspHs can be classified 
into four major classes, based on the arrangement of the aromatic residues near the 4Fe-
4S cluster and the presence of N- and C-terminal extensions, and these structure features 
are related to the environments in which IspHs are found. These aromatic groups protect 
the 4Fe-4S clusters from oxidation and are also involved in electron transfer. The results 
revealed how nature has evolved different structure features for a sensitive protein in 
different environments. 
In addition, another terpene biosyntheis enzyme, MenA, and two other 
metalloenzymes that are drug targets, DHAD and LOX, were also investigated. Overall, 
this research is of interest since it revealed the structure and functions of the terpene 
biosynthesis enzyme IspH from various organisms, as well as other proteins that are 
possible drug targets. 
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Chapter I 
Introduction 
 
1.1 Infectious Diseases and Antibiotic Resistance 
Infectious diseases, caused by microorganisms such as virus, bacteria, fungi or 
parasites, have been a major cause of lethality in the history of human beings. The 
introduction of synthetic antibiotics, most notably the development of penicillin, opened 
a “Golden Age” of antibiotic discovery after WWII. However, the number of newly 
discovered antibiotics decreased steeply only shortly afterwards, and most newly 
developed antibiotics belong to existing families.1 In the meanwhile, drug-resistant and 
multi-drug resistant strains, such as methicillin-resistant Staphylococcus aureus (MRSA), 
vancomycin-resistant enterococcus (VRE), and multi-drug resistant Mycobacterium 
tuberculosis, have emerged. The rise of antimicrobial resistance is due to, of course, the 
nature of evolution, but perhaps more importantly, misuse of antibiotics. The appearance 
of drug-resistant pathogens and the limited number of effective antibiotics have been a 
significant threat to the public health in this century, as pointed out by the reports from 
the US Centers for Disease Control and Prevention (CDC)2 and the World Health 
Organization (WHO).3 Apparently, there is an urgent need for new antibiotics, and these 
compounds need to inhibit new targets to avoid the existing resistant gene pool. 
In this research, I investigated the biochemistry and inhibition of several novel targets 
for infectious diseases, including enzymes involved in terpene and branch-chain amino 
acids biosynthesis, as described below. In addition, lysyl oxidase, a copper enzyme 
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involved in metastatic bone lesion, was also studied. These studies provided insights into 
new biochemistry and new strategies of various diseases. 
 
1.2 Terpene Biosynthesis, MEP Pathway and IspH 
Terpenes constitute a large class of functional and structural diverse natural products 
present in nearly every living creature.4 Shown in Figure 1.1 are a few examples of terpenes 
with various structures and functions. Despite such diversity, all terpenes are derived 
from two universal precursors: dimethylallyl diphosphate (DMAPP) and isopentyl 
diphosphate (IPP), by a series of prenyltransferases and other enzymes. These two C5 
building blocks are synthesized in nature through two distinct pathways (Figure 1.2): the 
mevalonate (MVA) pathway found in archaea, eukaryotes, and some bacteria; and the 
methylerythritol phosphate (MEP) pathway found in most bacteria and the plastids of 
higher plants and apicomplexan parasites.5 Both pathways are essential for the survival 
of the host organisms. It is certainly a mystery why natural has evolved two distinct routes 
and there have been debates regarding their origin and common ancestor from which the 
two pathways diverged.6 Nevertheless, we can take this advantage to develop inhibitors 
targeting the MEP pathway that is not present in humans, with fosmidomycin, which 
inhibits deoxyxylulose 4-phosphate reductoisomerase, having reached clinical trials for 
Plasmodium falciparum malaria.7 In addition, it is also of interest to develop MEP 
pathway-targeting herbicides that are harmless to human and other mammals.8 
The last two steps of the MEP pathway are two consecutive reductions, mediated by 
two iron-sulfur proteins, IspG and IspH; both are investigated in our lab. My research 
was focused on the latter step, i.e., the reductive dehydroxylation of (E)-1-hydroxyl-2-
methyl-but-2-enyl 4-diphosphate (HMBPP) catalyzed by the enzyme IspH. In addition to 
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the abovementioned essentialness of IspH in terpene biosynthesis, HMBPP itself is a very 
potent “phosphoantigen” targeting γδ T cells (containing the Vγ2Vδ2 T cell receptor) and 
activated γδ T cells kill tumor cells,9 so IspH inhibitors also have the potential to be novel 
immunotherapeutics. 
IspH is a 4Fe-4S cluster-containing protein in which the cluster is bound to the 3 
conserved cysteine residues in the protein backbone, and the 4th unique Fe being directly 
involved in the substrate binding and catalysis, Figure 1.3A. There have been numerous 
studies on the mechanism of IspH, based on which some potent inhibitors has been 
developed, Figure 1.3B.10 As shown in Figure 1.3C, the proposed mechanism of IspH 
consists of two consecutive one-electron transfer steps with a HIPIP (high-potential iron 
protein)-like [Fe3S4]3+-allyl anion intermediate.10-11 In addition, several X-ray structures 
of IspHs from different organisms have also been reported, with substrate, inhibitors 
bound or unliganded (exogenous) Fe-S clusters.12 These studies on IspH have drawn a 
clear picture of this important enzyme for us. Nevertheless, the wealth beneath it has 
never been exploited. During my research, I noticed several structural and sequence 
features of IspHs that are related to the physiology of the host organisms and provide 
insights into bacteria physiology and evolution, and two interesting stories are developed.  
Firstly, by analyzing the sequence similarity network of IspH family proteins, we 
identified that in many cases, the IspH domain is fused to another protein. Most 
commonly (yet still uncommon compared to regular single-domain IspH), IspH is fused 
to the ribosomal protein S1, while in several other cases, IspH forms hybrid with the 4-
hydroxybenzonate polyprenyltransferase family protein, UbiA. All IspH hybrids proteins 
were found in obligate anaerobic bacteria. Iron-sulfur cluster containing proteins are 
known to regulate translation, in response to changes in environmental Fe or O2 level, 
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such as fumarate and nitrate reduction regulator (FNR) and cytosolic aconitase. The fact 
that IspH forms hybrids with RPS1, and RPS1 is involved in translation initiation where 
Shine-Dalgarno sequences are degenerated, strongly indicates that IspH might also be 
involved similar regulatory mechanism in these organism. Given the reactive oxidation-
sensitive nature of IspH, and the fact that IspH hybrids are all from anaerobic bacteria, it 
seems plausible that this protein fusion event is related to oxygen sensing/regulation.  
This study is described in Chapter II.13 
Secondly, by comparing the X-ray structures of IspH from different organisms, we 
found that in some organisms such as E. coli and Plasmodium falciparum IspH, an extra 
C-terminal extension is present, covering the electron transfer side of the 4Fe-4S cluster. 
Moreover, based on the arrangement of the aromatic residues and the presence or 
absence of the N- or C-terminal domains, IspHs from different organisms can be divided 
into different classes that are broadly correlated to the environment where these IspHs 
can be found—from anaerobic/microaerophilic bacteria to aerobic bacteria, 
photosynthetic organisms, and intracellular protozoan pathogens. Further studies 
indicated that this C-terminal extension, along with the aromatic residues near the 4Fe-
4S cluster, have significant effects on the activity and stability of IspHs from different 
organisms, revealing their roles in cluster stabilization and electron transfer. The results 
here show how nature has evolved to enable organisms to survive in diverse environment. 
This study is described in Chapter III. 
The studies here suggested that, in addition to the well-known role of IspH in 
biosynthesis, it might also be involved in more sophisticated regulation events inside cells, 
which greatly expanded our knowledge to this enzyme, as well as the MEP pathway. 
 
5 
 
1.3 Branched-Chain Amino Acid Biosynthesis and DHAD 
Among of the 20 canonical amino acids that build up the protein world, several are 
essential to us since our body cannot synthesize them, such as the branched-chain amino 
acids valine, leucine and isoleucine. On the other hand, bacteria can synthesize these 
amino acids through the biosynthetic pathway, Figure 1.4. The concept of inhibiting the 
biosynthesis of these amino acids seems not to be a general effective anti-infective 
strategy since the pathogens would usually be assumed to scavenge amino acids from 
their host. However, branched-chain amino acids are not able to penetrate the 
phagolysosome that contains M. tuberculosis inside macrophage, making amino acid 
starvation an attractive and novel strategy for latent bacilli that are difficult to treat.  
What draws our interests are two 4Fe-4S cluster-containing enzymes, dihydroxyacid 
dehydratase (DHAD) involved in valine, leucine and isoleucine biosynthesis and 
isopropylmalate isomerase (LeuCD) involved in leucine biosynthesis. Specifically, DHAD 
is essential for the survival of M. tuberculosis cells in vitro, and M. tuberculosis 
transformed with a plasmid encoding anti-sense mRNA had poor growth in vivo, but 
growth was normal when the medium was supplemented with ILV.14  DHAD is thus an 
attractive target for novel tuberculosis therapy.  
In my research, both E. coli and M. tuberculosis DHAD are cloned, expressed and 
purified. A high-throughput enzymatic assay system was developed for this protein. We 
synthesized ~40 compounds that were analogues to the reported herbicide leads targeting 
spinach and E. coli DHAD, developed by DuPont. Several low micromolar inhibitors were 
identified, and their cell activities were tested. Meanwhile, crystallization of DHAD is also 
ongoing in collaboration with Dr. Groll. This work is described in Chapter IV.  
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1.4 SQ109 and Multi-targeting Drug Discovery 
Tuberculosis has long been a significant threat to public health. While several drugs 
and cocktail therapies have been developed, it still draws much attention due to the 
appearance of multi-drug resistance strains, and therefor new drugs are necessary. SQ109, 
Figure 1.5, is a potent lead compound identified from a screening program of ~64000 
ethylenediamine analogues of anti-tuberculosis drug ethambutol.15 It has a MIC90 value 
of ~1 µM against various M. tuberculosis strains including the multi-drug resistant one. 
More interesting, resistance was not unable to develop in evolution experiment,16 
suggesting a complicated mode of action.  
In our study,17 we synthesized a series of SQ109 analogues, tested their activity against 
several pathogens, and studied the mode of action of these analogues.  Our result revealed 
that SQ109 analogues act on a series of targets including prenyltransferases involved in 
quinone biosynthesis, ATP synthesis, and the proton motive force. In a follow-up study,18 
a broad range of various SQ109 analogues (~50) were synthesized, and they were tested 
against a panel of pathogens and human cell lines. Unexpectedly, some of the SQ109 
analogues are potent inhibitors of Trypanosoma brucei, the causative agent of African 
trypanosomiasis, a.k.a., the sleeping sickness; and they all have good therapeutic index. 
This study is described in Chapter V. 
 
1.5 Cancer Metastasis and Lysyl Oxidase 
Metastasis is a common disease as cancer proceeds and significantly increases a 
patient’s likelihood of death, yet its mechanism is usually complicated and largely 
unknown. Breast cancer, for example, metastasizes to bone in ~85% of patients in 
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advanced stage and renders them largely untreatable. Bone metastasis is accompanied by 
osteolytic bone lesions which eventually destroys bones, leading to severe patient 
morbidity and mortality. Recently, the mechanism of breast cancer-associated bone 
metastasis was investigated.19 In oestrogen-receptor negative breast cancer, high 
expression of lysyl oxidase (LOX) was shown to be significantly associated with osteolytic 
bone lesion by disrupting normal bone hemostasis, leading to pre-metastatic niche. This 
discovery opened up new therapeutic possibilities that LOX inhibitors could be used to 
treat metastasis-associated bone lesion. 
LOX is annotated to be a copper amine oxidase, presumably containing a type II copper 
center ligated by histidines and waters. Numerous studies have been carried out for LOX, 
mainly on its regulation and correlation to cancers. However, the biochemical 
fundamentals of this enzyme have never been elucidated. The difficulties of studying LOX 
are mainly due to its very low solubility and activity. There are a few reports on the 
cloning/expression/characterization of human or drosophila LOX,20 but many of these 
did not provide enough information, or are not reproducible. 
In our study, we aimed to study to coordination sphere of the copper atom in lysyl 
oxidase. We tried to express different LOXs from human, bacteria and drosophila. 
Fortunately, we were able get a decent sample of drosophila LOX, with good purity and 
over ~100-fold activity compared to reported values. We obtained the CW- as well as the 
pulsed EPR spectra of this protein, providing insights into its active site structures and 
catalytic mechanism. Interestingly, we also found that certain bacteria, mainly 
myxobacteria, also contain a LOX that shares moderate homology to LOXs found in 
mammals. This study is described in Chapter VI. 
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1.6 Research Strategies 
First, a large portion of my research is associated with metalloproteins: IspH and 
DHAD contain 4Fe-4S clusters, and LOX contains copper. These metal centers all 
contains unpaired electrons at certain condition. Therefore, electron paramagnetic 
resonance (EPR) is a useful technique to study these proteins. Previous work in our lab 
has investigated the mechanisms of IspG/H intensively with both continuous-wave and 
pulsed EPR techniques. In my study with IspH, cw-EPR was mainly used as routine 
analysis of the cluster, and with LOX, pulsed EPR has been used to elucidate more 
detailed structural information regarding the copper center. 
Second, the rapidly increasing database of genome sequencing data has shown to be 
invaluable wealth. Genome mining for biosynthetic gene clusters has been a large area of 
interest studied by a variety of groups. Here, we showed that comparative genomics also 
provides important information regarding the function of important proteins and their 
evolution. By using a sequence similarity network, we identified the existence of IspH 
fusion protein IspH-RPS1 and IspH-UbiA, suggesting possible regulatory roles of IspH. 
By aligning the sequences and structures of IspH, we also identified different classes of 
IspH based on their active site environment arrangement. These analysis has provided 
valuable information regarding the enzymes from a different perspective, and allow us to 
think in a bigger picture. 
Molecular biology tools, such as cloning and site-directed mutagenesis, are crucial to 
obtaining interesting target for investigation.  
And last, enzyme kinetics, various spectrophotometry methods and LC-MS are used to 
study the function of the enzymes. 
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1.7 Figures 
 
 
Figure 1.1 Naturally existing terpenes and the two C5 universal precursors from which 
they are biosynthesized.  Menthol is the source of the mint flavor. Menaquinone is used 
to transfer electrons in cell respiration. Retinol, a form of vitamin A, is a precursor of the 
cofactor of rhodopsin, the vertebrate photoreceptor. Cholesterol is the essential structural 
component of animal cell membrane. Artemisinin is a novel anti-malaria drug that has 
the most rapid effects against Plasmodium falciparum malaria. Gibberellic acid is a 
growth hormone found in plants and fungi. 
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Figure 1.2 The methylerythritol phosphate pathway. Shown in red are the two enzymes 
of interest to us. 
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Figure 1.3 Structure, mechanism and inhibitors of IspH. (A) X-ray structure of E coli 
IspH (PDB code: 3KE8). Yellow: Fe4S4 cluster. Purple: HMBPP. (B) Active site structure 
of IspH showing residues crucial for catalysis. (C) Proposed mechanism of IspH catalysis. 
(D) Mechanism-based inhibitors for IspH. The alkyne or pyridine nitrogen binds to the 
4th Fe in the 4Fe-4S cluster, inhibiting the catalysis. 
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Figure 1.4 Biosynthesis of branched-chain amino acids: leucine, valine and isoleucine. 
 
 
Figure 1.5 Structure of SQ109, a tuberculosis lead compound. 
 
 
Figure 1.6 The role of lysyl oxidase in breast cancer metastasis-induced bone lesion. 
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Chapter II   
IspH-RPS1 and IspH-UbiA: “Rossetta-stone” proteins 
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2.2 Introduction 
The methylerythritol phosphate pathway is responsible for the production of the 
terpene building blocks dimethylallyl diphosphate (DMAPP, 1, Scheme 2.1) and 
isopentenyl diphosphate (IPP, 2, Scheme 2.1) in most bacteria, apicomplexan parasites, 
and plants. Its component enzymes are all essential for survival, so there is interest in 
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their inhibition1 for the development of drugs to treat infectious diseases, such as malaria 
and tuberculosis, with fosmidomycin2, which inhibits deoxyxylulose 4-phosphate 
reductoisomerase, having reached clinical trials for malaria3. In addition, targeting the 
pathway could be of use for herbicide development. IspH, (E)-1-hydroxy-2-methyl-but-
2-enyl 4-diphosphate (HMBPP, 3, Scheme 2.1) reductase, also known as LytB (but not to 
be confused with the N-acetylglucosaminidase LytB from Streptococcus spp.), is the last 
enzyme in the pathway.4 IspH is a 4Fe-4S cluster-containing protein5 that catalyzes the 
2H+/2e- reductive dehydroxylation of HMBPP into a ~1:5 mixture of dimethylallyl 
diphosphate and isopentyl diphosphate. Its structure and mechanism of action have been 
studied extensively, both experimentally6 and computationally,7 and several inhibitors 
have been developed.6a The mechanism of action is remarkable and the consensus view 
now is that IspH utilizes a bio-organometallic mechanism in which an allyl species binds 
to the Fe-S cluster.7 
     Despite their now well-known role in isoprenoid biosynthesis, IspHs (known as 
LytBs at the time) from E. coli and Campylobacter jejuni were first identified and 
investigated almost 20 years ago in studies of the so-called “stringent response”, in 
bacteria.8 The stringent response is a stress response that can arise from diverse insults 
and is aimed at limiting growth to promote survival. An IspH mutant E. coli strain WV78b 
induced the stringent response and exhibited a penicillin-tolerant phenotype at restrictive 
temperatures (42 oC). This phenotype could be complemented by wild-type E. coli IspH 
or C. jejuni IspH,8a but not by a C. jejuni IspH Q265H mutant and it was proposed that 
the wild-type IspH could interact “directly or indirectly” with RelA.8b RelA is an enzyme 
that has been shown to bind to the bacterial ribosome9 and is responsible for biosynthesis 
of the alarmone, (p)ppGpp, guanosine tetraphosphate (or pentaphosphate), the key 
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regulator involved in the bacterial stringent response.10 In addition, RelA is an emerging 
central regulator of multidrug tolerance and persistence.11 If the interaction between IspH 
and RelA were disrupted, the stringent response would be induced.  
     In other work it has been noted that that some bacterial proteins appear to contain 
a fusion in which IspH is linked to another ribosomal protein, RPS1, the ribosomal protein 
small (30S ribosome) protein 1.12 Fusion hybrids are often found when two individual 
proteins have some related activity and are called "Rosetta stone" proteins13 and RPS1-
IspH is given as one13b example, although the functional relatedness of the 2 domains has 
not been proposed. Here, we report initial cloning, expression, purification, activity, 
inhibition, mutagenesis and spectroscopic results on one IspH-RPS1 protein. In addition, 
we report that several other proteins form fusion hybrids with IspH, one of which appears 
to be a functionally related prenyl synthase. 
 
2.3 Results and Discussion 
2.3.1 IspH-RPS1: A Rosetta-stone protein present in many gut bacteria, 
and some human pathogens.  
We first investigated the network of IspH family proteins by using the Enzyme 
Similarity Tool from the Enzyme Function Initiative (EFI-EST; 
http://efi.igb.illinois.edu/efi-est/) to generate a sequence similarity network for IspH 
family proteins, and visualized the results by using Cytoscape.14 An overview of 15,660 
IspHs is shown in Figure 2.1. Most can be sorted into clusters based on the phylum and 
class of the organism. In a network with an expectation value of 10-120 , the major clusters 
shown in Figure 2.1 are as follows: a, Gammaproteobacteria (dark cyan, upper left) and 
Betaproteobacteria (blue, lower right); b, Alphaproteobacteria (cyan); c, Firmicutes 
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(purple); d, Firmicutes (with very long sequences, red); e, Bacteroidetes (yellow); f, 
Actinobacteria (orange); g, Cyanobacteria and plants (green); h, Apicomplexa (pink, 
genus Plasmodium, the malaria parasites) and i, Desulfobacterales (brown, an order of 
Deltaproteobacteria).      
What is of particular interest about these bioinformatics results is that, unlike most 
bacterial IspHs—which typically have ~300 residues (e.g. E. coli, N=316 residues, and 
Aquifex aeolicus, N=297 residues)—the IspHs found in cluster D (and a few isolated 
nodes) are much larger, with N~600-850 residues. In most cases this is due to a fusion 
with several ribosomal protein S1-like tandem repeats, found in the ribosomal protein S1 
(RPS1) in the 30S subunit of the bacterial ribosome. The basic IspH-RPS1 architectures 
are shown schematically in Figure 2.1j. Notably, essentially all of the organisms that have 
the IspH-RPS1 fusion are anaerobic bacteria. Among the 447 IspH-RPS1 sequences, 157 
are from anaerobes. The other 290 are not annotated, but are primarily from anaerobic 
species. As shown in the zoomed-in view of the IspH-RPS1 network (Supplementary 
information, Figure 2.2), the majority of the IspH-RPS1s are from Firmicutes, the low 
G+C gram-positives, including many members from the genus Clostridium. They include 
pathogens such as C. tetani and C. botulinum (the causative agents of tetanus and 
botulism, respectively), as well as the industrially valuable strain, C. acetobutylicum. A 
few IspH-RPS1s are from gram-negatives and typically contain 6 S1 repeats, Figure 2.1j, 
one example being Fusobacterium nucleatum. This organism plays a role in periodontal 
disease as well as being associated with colorectal carcinoma15 where it is involved in 
protecting tumors from immune system (NK cell) attack.16 We also found that 37% of the 
IspH-RPS1s are present in the human gut, examples being Clostridium sp. SS2-1, 
Eubacterium hallii, Subdoligranulum variabile, Clostridium leptum,  Coprococcus 
21 
 
eutactus, Clostridium sp. L2-50, Anaerotruncus colihominis, and Clostridium 
asparagiforme, the first two organisms being the 7th and 9th most abundant gut bacteria.17  
     As noted in the book chapter by Pellegrini and Graeber,13b the IspH-RPS1 fusion 
hybrids are thought to be examples of Rosetta stone proteins, functionally-related fusion 
proteins, rather than having arisen from random fusion events. However, there have been 
no proposals as to what the non-IspH function might be, rather, it is the high occurrence 
of IspH-RPS1 hybrids that is suggestive of functional relatedness.  
2.3.2 IspH forms other fusion hybrids.  
Inspired by the observation of large numbers of IspH-RPS1 fusion proteins, we next 
examined the sequences and conserved domains of all IspHs in the sequence similarity 
network. In addition to the IspH-RPS1 fusions and the plant/protozoan IspHs (that 
appear to have an N-terminal plastid-localization domain), there are five other types of 
IspH fusion annotated (Figure 2.1k; Figure 2.3). The most abundant fusion is between 
IspH and a putative prenyltransferase, typically annotated as a UbiA (4-hydroxybenzoate 
octaprenyltransferase) family protein. There were 47 such sequences found, primarily in 
the gram-negative sulfate-reducing bacteria Desulfobacterales (cluster i in the Cytoscape 
network, brown, Figure 2.1i) in which the UbiA-like prenyltransferase domain was fused 
to the C-terminus of IspH, Figure 2.1k. UbiAs form a superfamily of proteins, Figure 2.4, 
typically thought to contain ~9 trans-membrane helices, and the X-ray structure of UbiA 
has recently been reported.18 The function of the UbiA-annotated domain in the IspH-
UbiAs, categorized as PT_UbiA_5, is unknown, However, it has been reported that 
ubiquinones are not detected in sulfate-reducing bacteria;19 that menaquinone-7 is the 
major respiratory quinone in these organism; and a separate UbiA/MenA is evident in 
their genomes. It seems likely, nevertheless, that the UbiA domain is involved in prenyl 
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transferase activity, not least since there are two "DXXXD" repeats present, typical of 
prenyl synthases and transferases, and the fact that IspH appears to be fused to a second 
prenyltransferase would of interest since it suggests that the fusion may be functionally 
significant-a true Rosetta stone protein. In addition, the hybrid protein would likely be 
membrane-bound. Four other types of fusion were found only in single species (or several 
strains of the same species): CMP kinase; helicases; fructose bisphosphatase and 
UDP/PNP phosphorylase (Figure 2.3a-d). Plus, in a recent report,20 IspHs from a 
cyanobacterium and a plant, photosynthetic organisms, were proposed to have an extra 
N-terminal conserved domain and a conserved Tyr (Figure 2.3e), to protect the enzyme 
from high oxygen levels during photosynthesis, although this domain appears to be a 
simple IspH modification.  
2.3.3 Organization and structure prediction for IspH-RPS1 and IspH-UbiA. 
We next sought to begin to investigate the possible structures of the IspH-RPS1 and 
IspH-UbiA hybrids. RPS1s from most gram-positive bacteria (e.g. Bacillus subtilis) 
contain 4 S1-like repeats, Figure 2.1j (top), while RPS1s from gram-negatives (e.g. E. coli) 
typically contains 6 S1-like repeats, Figure 2.1j (bottom). In E. coli, the first two repeats 
are used for ribosome binding21, and the last four repeats for mRNA binding during 
translation-initiation. There have been no X-ray structures of any IspH-RPS1s reported. 
The structures of small bacterial and a protozoal IspH have, however, been reported,6b, 22 
and by way of example, we show that of the E. coli protein in Figure 2.5a, together with 
that of the P. falciparium protein (N=318, the apicoplast-targeting domain being  absent), 
in Figure 2.5b.23  
     Both the E. coli and P. falciparum structures are characterized by a trefoil/clover-
leaf arrangement of α/β domains with the catalytic 4Fe-4S cluster at the center of each 
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structure, linked to the protein via 3 Cys thiols. Substrate, inhibitor or water molecules 
occupy the remaining coordination sites. By way of comparison, a computational (Phyre2  
program24) structure prediction of the Clostridium thermocellum IspH-RPS1 protein is 
shown in Figure 2.5c. The trefoil-like IspH domain is well defined, plus there are four 
more (and less) defined RPS1 domains (which are based on the solution NMR structures 
of individually expressed RPS1 domains).12b  
     A Phyre2 structure prediction of the Desulfobacula toluolica (a marine, aromatic 
compound-degrading, sulfate-reducing bacterium) IspH-UbiA is shown in Figure 2.5d. 
The UbiA domain is essentially that seen in the X-ray structure of Aeropyrum pernix 
UbiA18 (the template used by the Phyre2 program) and the 3 conserved Cys (yellow 
spheres) in the IspH domain and the two Asp rich (DXXXD) sites in the UbiA domain 
(purple spheres) can be readily identified. The UbiA domain is predicted to contain 9 
trans-membrane helices, and the IspH domain presumably lies on the cytoplasmatic side 
of the membrane, as shown in Figure 2.5d, although in most predicted structures this 
localization was variable. 
     In addition to the 3 essential Cys found in all IspH family proteins, involved in 
coordinating the 4Fe-4S cluster, IspH-RPS1s contain significantly more Cys than do the 
more conventional IspHs:  7.4 versus 4.8 on average (in the IspH domain), and some 
strains (Clostridium sp. CAG: 678; Mogibacterium sp. CM50) contained as many as 14 
Cys. The high cysteine content is probably related to the observation that most of the 
species are anaerobes, since it has been pointed out that cysteine depletion occurs on a 
proteome-wide scale on moving from anaerobic to aerobic unicellular organisms.25 The 
range of Cys content in the IspHs is, however, much larger than the proteome-wide 
average.      
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     At present, there is no information as to whether there are important functional 
consequences of the IspH-RPS1 (or other) fusions. Thus, as a first step toward answering 
that question, we next sought to express an IspH-RPS1, the most abundant IspH fusion 
protein, in order to form a basis for future studies of structure and function.  
2.3.4 Cloning, expression, purification and catalytic activity of IspH-RPS1. 
Since we did not find any other ispH or rps1 genes in the organisms that harbor ispH-
rps1, it is almost certain that the IspH domain makes IPP/DMAPP, since mevalonate 
pathway enzymes are absent in the genome. We first sought to see if IspH-RPS1 could be 
expressed and purified in an active form, catalyzing IPP/DMAPP formation from HMBPP. 
We attempted expression of IspH-RPS1s from three bacteria: F. nucleatum, C. 
acetobutylicum, and C. thermocellum. Initial trials with F. nucleatum and C. 
acetobutylicum resulted in low expression yields or inactive protein, although UV-Vis 
spectra clearly indicated the presence of a Fe-S cluster with C. acetobutylicum IspH-RPS1. 
Fortunately, active (in an HMBPP reduction assay) C. thermocellum (Cth) IspH-RPS1 
could be readily expressed in E. coli with moderate yields (~3 mg/L). C. thermocellum is 
an anaerobic, thermophilic bacterium that is of commercial interest since it catalyzes the 
direct conversion of crystalline cellulosic biomass into ethanol.26  
CthispH-rps1 encodes a single polypeptide of 694 residues and contains 4 S1-like 
repeats in the RPS1 domain. It was purified as an 81.2 kDa protein (with an N-terminus 
His6-tag) and its identity was verified by MALDI-TOF with an error of < 0.1% (Figure 2.6a, 
[M1+H]+, expected: 81309.0, found: 81233.9). However, there was poor iron-sulfur 
cluster incorporation, typically ~10%, even when co-expressed with the IscS protein27 that 
catalyzes cluster formation. We thus next used an in vitro reconstitution method with an 
expressed and purified IscS. The UV-Vis absorption spectrum of the reconstituted 
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CthIspH-RPS1 protein at 410 nm, Figure 2.6b, is consistent with the presence of an 
"oxidized" [Fe4S4]2+ cluster. This could be reduced by dithionite to the reduced [Fe4S4]+ 
cluster, as found with other IspH proteins.28  
     We then examined the catalytic activity of CthIspH-RPS1 in the conversion of 
HMBPP into DMAPP and IPP by using the methyl viologen assay described previously.29 
As shown in Figure 2.6c, the enzyme has a kcat of 56 min-1 and a Km of 15 µM, at room 
temperature. The kcat is very close to the value found with IspH from the thermophile 
Aquifex aeolicus while the Km is 2-fold larger (kcat=1.0 s-1; Km=7 µM).6a Substrate 
consumption and product formation were also confirmed by LC-MS (Figure 2.7) and 
NMR analysis. So, an IspH-RPS1 can be expressed from a thermophile and its activity is 
similar to that of IspH from another, "IspH-only", thermophile. 
2.3.5 Truncation mutants: effects on activity and 4Fe-4S cluster-binding.  
In order to find out whether the presence of the RPS1 domain had any effects on the 
catalytic activity of CthIspH-RPS1, we made truncation mutants containing 0, 1, 2 or 3 
S1-like repeats (called here D0, D1, D2, D3; cartoon in Figure 2.6d). As shown in Figure 
2.6e, these truncation mutants had almost the same activity as the wild-type CthIspH-
RPS1 which contains 4 S1-like repeats, indicating that the RPS1 domain is not essential 
for IspH catalysis, at least in this in vitro assay. 
     We then investigated the 9 GHz EPR spectra of wild-type and truncation mutants of 
CthIspH-RPS1, Figure 2.6f, to see if there were any obvious differences in cluster 
electronic structure, due to RPS1 binding. The wild-type CthIspH-RPS1 spectrum (Figure 
2.6f, pink) had g values of [2.022, 1.910, 1.896, 1.826] in the g~2 region, typical of reduced 
S = 1/2 Fe4S4 cluster. In addition, an isotropic signal at g=5.0 was assigned to an S = 7/2 
species (see Figure 2.8 for simulation), similar to a previously observed [Fe4S4]+ cluster 
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from benzoyl-CoA reductase.30 By way of comparison, higher-spin species were not as 
obvious in E. coli IspH (Figure 2.6f, yellow), and the g values at g~2 were also slightly 
lower [1.998, 1.900, 1.873, 1.791]. The mutants all exhibited essentially the same EPR 
spectra as the wild-type C. thermocellum protein. We also made (though not by design) a 
very short C. thermocellum IspH (residues 1-171; "Cth171") in which the C-terminal "leaf" 
of the cloverleaf was excised. Although inactive and missing the third essential Cys, the 
protein still bound a reducible Fe/S cluster and had an EPR spectrum very similar to that 
of the other IspHs, as shown in Figure 2.6g.  However, unlike the other unliganded IspHs, 
Cth171 exhibited just the strong signal in the g~2 region, and the spectra did not change 
upon ligand (3, 4, 5 and 8) binding, Figure 2.6g and Figure 2.9. Apparently, the 3 Cys 
residues are not essential for cluster binding, but are for ligand binding. 
2.3.6 IspH-RPS1 inhibition and a comparison with other IspHs.  
We next investigated the inhibition of CthIspH-RPS1 catalytic activity with the 
inhibitors (4-12) developed previously,6a, 31 as well as a new compound (13).  The interest 
here is that it might be possible to develop compounds that specifically inhibit F. 
nucleatum cell growth, reinstating, perhaps, the cytotoxicity of NK cells against colorectal 
carcinomas.15-16 
     Structures of the compounds tested are shown in Figure 2.9a and consist of various 
alkyne and pyridine diphosphates and phosphonates. Representative dose-response 
inhibition curves are shown in Figure 2.9b. These and other inhibition results are 
summarized in Figure 2.9a together with Aquifex aeolicus IspH inhibition results. As a 
class, the acetylenes were the most potent inhibitors. The best inhibitor for CthIspH-RPS1 
was the alkynyl compound 5, which had an IC50 of 3.3 µM. Compound 5 was also the most 
potent alkyne inhibitor for AaIspH, where it had the lowest IC50, 0.45 µM. The pyridine-
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containing compounds were, in general, weak inhibitors. Interestingly, a novel alkynyl 
thioester compound (i.e. with a P-S bond), 13, was also very active against CthIspH-RPS1, 
compared to the ester compound 11. This thioester feature could potentially be useful in 
developing more drug-like leads that are resistant to hydrolysis, although pro-drugs will 
likely be needed for good cell penetration.  
     To investigate IspH-RPS1 ligand-protein interactions in more detail, we obtained 9 
GHz EPR spectra of liganded (the acetylene 4, the pyridine 8, and the thiolo -diphosphate 
13), reduced CthIspH-RPS1, Figure 2.9c. Upon binding of the alkynes 4 or 13, the signal 
from the higher-spin species in the unliganded spectrum disappeared and the signal 
intensity of the spin S = 1/2 species increased, with g values of [2.099, 2.012, 1.999] in 
the case of 13, similar to the values found with the alkyne inhibitors reported previously, 
bound to EcIspH and AaIspH.6a Pyridine compounds such as 7-10 are another class of 
IspH inhibitors, but these all had only weak activity against CthIspH-RPS1, resulting in a 
significant amount of unliganded signal in the EPR spectrum of 8, despite the ligand 
being present in a 20-fold excess.  
2.3.7 IspH-RPS1 binds to E. coli transcription termination factor Rho.  
A surprising observation during protein expression and purification was that when 
heterologously expressed in E. coli, CthIspH-RPS1 always co-purified with a protein of 46 
kDa, as seen in the MALDI spectrum in Figure 2.6a. This protein (M2, Figure 2.6a) bound 
strongly enough to CthIspH-RPS1 that it co-purified with a CthIspH-RPS1 construct 
containing both a His-Tag and a Strep-Tag, in a two-step affinity chromatographic 
purification. The binding partner was subsequently found to be the E. coli transcription 
termination factor Rho through protein MS fingerprint analysis (Figure 2.10a), with a 
sequence coverage ratio of 69%. The Rho factor is a helicase that unwinds the DNA-RNA 
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junction during transcription termination and has a strong binding affinity for 
nucleotides.32 It seemed possible that the binding between CthIspH-RPS1 and EcRho 
might also be mediated by nucleotide binding and indeed, we found that Rho could be 
dissociated from CthIspH-RPS1 by washing the Ni-NTA resin with a 0.5 mM (CT)4 DNA 
oligomer, a reported Rho binder in an X-ray study33 (Figure 2.10b). It is also of interest 
that there is an actual (i.e., annotated) IspH-helicase fusion protein, in Bacteroidales 
bacterium CF, Figure 2.3b.  
2.3.8 IspH-RPS1 hampered growth of E. coli cells.  
Overexpression of IspH-RPS1 in E. coli introduces a foreign ribosomal protein. 
Overexpression of E. coli RPS1 was shown previously to competitively bind to the native 
E. coli ribosome and inhibit the function of ribosome.34 In our study, we indeed observed 
that E. coli cells harboring CthIspH-RPS1 grew much slower than the same strain 
expressing other proteins, and this effect was much less significant for the truncation 
mutants of CthIspH-RPS1, Figure 2.11. It is thus interesting to see that a foreign ribosomal 
protein, from a thermophile, can bind, partially, to the E. coli ribosome and impaired the 
cell growth. 
2.3.9 Possible roles of IspH-RPS1 and IspH-UbiA.  
The roles of the IspH fusions in IspH-RPS1 and IspH-UbiA remain to be determined. 
What is, however, clearly of interest is that there are hundreds of anaerobes that contain 
IspH-RPS1 hybrids, many are found in the human gut, and some are pathogens or 
carcinogens. The very observation that IspH-RPS1 proteins exist supports previous ideas 
derived from work with E. coli (that lacks the RPS1 fusion) that the IspH domain might 
bind close to RelA when IspH-RPS1 binds to the ribosome, Figure 2.12. Combining these 
results and ideas with the results of MS, EM and microbiological studies,8-9, 21 we propose 
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that the 4Fe-4S cluster might act as a  “switch” to probe iron or oxygen levels, affecting 
RelA activity and the stringent response, a moonlighting35 4Fe-4S cluster containing 
protein that would be reminiscent of the fumarate-nitrate reductase regulatory protein, 
FNR,36 or perhaps of aconitase, another 4Fe-4S protein that has recently been found as a 
fusion with another ribosomal protein, bL21.37 Likely, the 4th water-ligated Fe-center6g of 
the 4Fe-4S cluster may dissociate to trigger a conformational change of the protein, as 
found in early IspH structures with 3Fe-4S clusters.6b, 38  
The question then arises as to the rational mechanisms of the regulatory roles of IspH-
RPS1. As a few examples, FNR, when the integrity of the 4Fe-4S cluster is disrupted, acts 
as transcription regulator to induce expression of hundreds of genes in E. coli.36 Similarly, 
cytosolic aconitase, in its apo-form, binds to iron responsive element receptor to regulate 
iron hemostasis.39 Bacterial aconitases, such as AcnA and AcnB in E. coli, in their apo-
form, were shown to bind to the 3’-untranslated region (UTR) of their own mRNA and 
stabilize them, resulting in an enhanced expression when oxidative stress is high.40 These 
examples indicated a strong correlation between Fe-S cluster-containing proteins and 
Fe/O2 sensing. RPS1 is known to initiate the translation by binding to the “AU”-rich 
region on the 5’-UTR of many genes, especially when the Shine-Dalgarno sequences are 
degenerated.41 In addition to its function in translation initiation, the C-terminus of RPS1 
is also involved in the so-called “trans-translation” by binding to the trans-messenger 
RNA (tmRNA) to rescue stalled ribosome in which the mRNA is replaced with a tmRNA 
followed by translation of a short tag peptide encoded by tmRNA.42 It is an important cell 
recovery mechanism in response to stress, virulence, nutrient deficiency.43 It is thus 
possible that IspH-RPS1 is involved in the regulation of the trans-translation process, and 
this hypothesis is currently under investigation.  
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With IspH-UbiA, there are fewer species (47) than found with the IspH-RPS1 hybrids 
(447) but this is still a large number (versus that expected for random fusions13a, <1). 
Again, all are found in anaerobes, so IspH might (again) act either as a sensor, or, perhaps 
more likely, the UbiA domain might localize IspH to the cell membrane, with IspH 
facilitating UbiA-like-protein product formation by providing high local levels of 
IPP/DMAPP (and hence, down-stream prenyl diphosphates). We attempted expression 
of IspH-UbiA fusion proteins from several sulfate-reducing bacteria: Desulfobacterium 
autotrophicum, Desulfobacca acetoxidans and Thermodesulfatator altanticus, but only 
succeeded in producing modest levels of IspH together with an UbiA domain fragment, 
most protein being truncated and appearing in inclusion bodies. The observation of 
several other, single-example, fusion hybrids, Figure 2.4, could be the result of random 
events, however, it is of interest that in every case, the IspH partner is involved in 
phosphorus metabolism: a helicase, kinase, phosphatase or a phosphorylase. 
 
2.4 Conclusion 
Overall, the results reported here are of interest since they show that active IspH-RPS1 
proteins can be expressed, and inhibited, of potential interest in the context of 
understanding the biology underlying IspH gene fusions, as well as in anti-infective and 
even anti-cancer drug discovery. There are many hundreds of organisms containing IspH-
RPS1, about 37% being human gut bacteria. Some of these are in pathogens such as 
Clostridium tetani, Clostridium botulinum, and in Fusobacterium nucleatum, an oral 
pathogen that is also being linked to colon carcinoma. We also found that there are ~47 
IspH-UbiA hybrids, all in sulfate-reducing bacteria, as well as smaller numbers of other 
IspH hybrids. We cloned, expressed and purified active IspH-RPS1 from Clostridium 
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thermocellum and found that it had similar activity to IspH from another thermophile, 
Aquifex aeolicus. The IspH-RPS1 protein contains IspH fused to 4 RPS1 repeats: removal 
of 1, 2, 3, or 4 of these domains had no effect on IspH catalytic activity. We investigated 
the inhibition of C. thermocellum IspH catalytic activity (conversion of HMBPP to 
DMAPP and IPP) by a series of alkyne and pyridine diphosphate and related inhibitors 
finding most potent activity with a novel alkyne thiolo-diphosphate, and the profiles of 
activity against both C. thermocellum and A. aeolicus were very similar. We also found 
that IspH-RPS1 bound to an E. coli protein, Rho, a helicase, and that there was evidence 
for an IspH-helicase fusion hybrid, in Bacteroidales bacterium CF. With IspH-UbiA, we 
were not successful in expressing full length active protein, but the observation of such 
hybrids is still intriguing given that both components are likely to be involved in 
isoprenoid biosynthesis. The IspH-UbiA hybrid is very likely to fit the functional 
definition of a Rosetta stone protein in which there are two domains that act in the same 
metabolic pathway. IspH makes DMAPP and IPP, and UbiA-like proteins utilize a diverse 
range of prenyl diphosphates. With IspH-RPS1, there are many fusion hybrids reported, 
but the functional-relatedness of the two domains is less clear. However, since RPS1 
proteins bind close to the RelA binding site on the bacterial ribosome, a role for IspH-
RPS1 in the bacterial stringent-response is a possibility, consistent with previous 
suggestions of an IspH-RelA interaction, although further work will be required in order 
to fully understand the mechanism of action of both hybrids. 
 
2.5 Materials and Methods 
2.5.1 Sequence similarity network.  
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The sequence similarity network for the IspH family proteins (InterPro number 
IPR003451) was generated by using the Enzyme Function Initiative Enzyme Similarity 
Tool (EFI-EST, http://efi.igb.illinois.edu/efi-est/). An expectation-value of 10-120 was 
used to construct the network, which was then visualized by using Cytoscape 3.2.1. A 
single node represents sequences with at least 90% identity, while each edge joins 
sequences that share an e-value of 10-120 or smaller.  
2.5.2 Cloning, protein expression, and purification.  
CthispH-rps1 and its mutants were amplified from the genomic DNA of Clostridium 
thermocellum strain VPI 7372 [ATCC® 27405TM] by polymerase chain reaction. The 
amplification product was digested with SacI-HF and SalI-HF (New England Biolabs, MA) 
and cloned into the pET-28a (+) vector (Novagen, WI). The plasmid with the correct 
insert was transformed into E. coli BL21-CodonPlus (DE3)-RIPL competent cells (Agilent, 
CA). For protein expression, six liters of LB broth supplemented with 25 mg/mL 
kanamycin and 17 mg/mL chloramphenicol were inoculated with a 0.5% overnight 
culture and grown at 37 °C to an O.D.600 of 0.6-0.8. Protein expression was induced by 
addition of isopropyl β-D-1-thiogalactopyranoside to a final concentration of 1 mM and 
the cultures were grown at 28 °C for a further 24 hrs.  The cells were then harvested and 
stored at -80 °C until further use. CthIspH-RPS1 and all mutants were purified by using 
column chromatography employing a Ni-NTA HispurTM resin (Fisher, NY), according to 
the manufacturer’s instructions. Briefly, cell pellets were thawed and suspended in the 
loading buffer (5 mM imidazole, 50 mM Tris/HCl, 150 mM NaCl, pH = 8.0) containing 
protease inhibitor cocktail tablet (Roche) and lysed by sonication. The cell debris was 
discarded after centrifugation and the clear cell lysate was loaded onto the resin. The resin 
was then washed (50 mM imidazole, 50 mM Tris/HCl, 150 mM NaCl, pH = 8.0) and the 
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desired protein eluted (300 mM imidazole, 50 mM Tris/HCl, 150 mM NaCl, pH = 8.0). 
Imidazole was removed by dialysis against storage buffer (50 mM Tris/HCl, 150 mM NaCl, 
1mM DTT, 5% glycerol, pH = 8.0). The molecular weight of wild-type CthIspH-RPS1 was 
confirmed with MALDI-TOF (Bruker UltrafleXtreme, Boston, MA) mass spectrometry. 
Purity of the proteins was checked with SDS-PAGE. Protein concentrations were 
determined by using the Bradford assay. The concentrations of the [Fe4S4]2+ clusters were 
measured by using UV-Vis spectroscopy. The extinction coefficient at 410 nm was taken 
to be 15000 M-1 ∙cm-1.44 
2.5.3 Fe-S cluster reconstitution.  
The Fe4S4 cluster of CthIspH-RPS1 and its mutants was reconstituted by using purified 
Azotobacter vinelandii IscS protein. AvIscS was expressed from a plasmid which was the 
kind gift from Professor James A. Imlay. Typically, as-purified IspH-RPS1 was 
concentrated to ~2 mL (~50-100 µM), degassed by bubbling nitrogen through the 
solution, transferred into an anaerobic chamber (Coy Labs, Grass Lake, IL), then stirred 
gently in the chamber overnight in order to equilibrate with the inert atmosphere. To the 
gently stirred protein solution was added 0.5 mM Fe(NH4)2(SO4)2, 2.5 mM L-cysteine, 5 
mM DTT and ~0.1 µM IscS. The reaction was incubated for several hours until Fe4S4 
incorporation was satisfactory, taken to be an A410/A280 ratio of ~0.4. The resulting 
protein solution was then centrifuged to remove any precipitate, desalted by using a PD10 
column (Agilent, CA) and concentrated as necessary. IscS was not removed from the 
sample since it represents only ~0.1% of the total protein.  
2.5.4 Enzyme kinetics and inhibition assay.  
The CthIspH kinetics and inhibition assays were performed by using the methyl 
viologen method described previously29. The final assay solution contained 40 nM 
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enzyme, 50 µM HMBPP, 40 µM dithionite and 2 mM methyl viologen. The reactions were 
monitored at 606 nm. Km and kcat were fitted by using a Michaelis–Menten relation in 
Origin 9.1. The extinction coefficient for the methyl viologen radical cation at 606 nm was 
taken to be 13700 M-1 ∙cm-1.45 
2.5.5 Electron paramagnetic resonance (EPR) spectroscopy.  
All sample preparation procedures were carried out in an anaerobic chamber. 
Reconstituted and desalted CthIspH-RPS1 was concentrated to ~0.3-0.4 mM and 20 
equivalents of Na2S2O4 and the ligand of interest, added. Samples (and no-ligand controls) 
were incubated for 30 min and then transferred into an EPR sample tube. EPR 
experiments were performed at X-band (9 GHz) using a Varian E-122 spectrometer 
together with an Air Products (Allentown, PA) helium cryostat. Spectra were obtained at 
10K at a 1 mW power level. 
2.5.6 Protein fingerprint analysis.  
The identity of the E. coli transcription termination factor Rho was assigned by protein 
fingerprint analysis in the Protein Science Facility at the University of Illinois at Urbana-
Champaign. Briefly, the sample containing the unknown protein was trypsin-digested and 
the resulting mixture analyzed by using electrospray ionization (ESI) tandem mass 
spectrometry in positive ion mode. The results were compared against a protein database 
using the Mascot program.46  
2.5.7 Synthetic protocols.  
All reagents were purchased from Aldrich (Milwaukee, WI). The purity of compounds 
investigated were confirmed by 1H, 13C and 31P NMR spectroscopy at 400 MHz or 500 
MHz performed on Varian (Palo Alto, CA) Unity spectrometers. High-resolution mass 
spectra were obtained at the University of Illinois Mass Spectrometry Laboratory. 
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Cellulose thin layer chromatography (TLC) plates were visualized by using iodine or a 
sulphosalicylic acid-ferric chloride stain. The syntheses and characterization of 4–12 
were described previously.31 
2.5.8 4-Hydroxybut-2-ynyl-S-thiolodiphosphate (13)  
Tris-(tetra-n-butylammonium)thiodiphosphate was prepared using a literature 
procedures.47 1-Chloro-4-hydroxy-2-butyne (52 mg, 0.5 mmol) in CH3CN (0.5 mL) was 
treated with 1.38 g (1.5 mmol) tris-(tetra-n-butylammonium)thiodiphosphate in CH3CN 
(2 mL)  at 0 °C. The reaction mixture was allowed to warm to room temperature over 8 h, 
then solvent was removed under reduced pressure. The residue was dissolved in 1 mL of 
cation-exchange buffer (49:1 (v/v) 25mM NH4HCO3/2-propanol) and passed over 90 
equiv of Dowex AG50W-X8 (100-200 mesh, ammonium form) cation-exchange resin, 
pre-equilibrated with two column volumes of the same buffer. The product was eluted 
with two column volumes of the same buffer, flash frozen, and lyophilized. The resulting 
powder was dissolved in 1 mL of 50 mM NH4HCO3, 2-propanol/CH3CN (1: 1 (v/v), 2 mL) 
added, and the mixture mixed on a vortex mixer, then centrifuged for 5 min at 2000 rpm. 
The supernatant was decanted. This procedure was repeated three times and the 
supernatants were combined. After solvent removal and lyophilization, followed by flash 
chromatography on cellulose column (2:1:1 (v/v/v) 2-propanol/CH3CN/50 mM 
NH4HCO3), a white solid 24 mg (yield 15 %) was obtained. 1H NMR (400 MHz, D2O): δ, 
4.05-4.03 (m, 2H), 3.44-3.40 (m, 2H); 13C NMR (125.7 MHz, D2O): δ, 82.46, 81.03, 49.89, 
18.43; 31P NMR (161.9 MHz, D2O): δ, 7.83 (d, J = 26.4 Hz), - 9.50 (d, J = 26.4 Hz); High-
resolution mass spectrometry (HRMS, ESI) calcd. for C4H9O7P2S [M+H]+, 262.9544; 
found 262.9543. 
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2.6 Figures and Schemes 
 
 
Scheme 2.1 IspH catalysis. The reaction involves the 2H+/2e- reductive dehydroxylation 
of (E)-1-hydroxy-2-methylbut-2-enyl-4-diphosphate (3) to dimethylallyl diphosphate (1) 
and isopentenyl diphosphate (2).  
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Figure 2.1 Sequence similarity network of the IspH family proteins with 15,660 
members constructed at an expectation-value (e-value) of 10-120. A single node represents 
sequences with at least 90% similarity. Major clusters of interest include: a, 
Gammaproteobacteria (dark cyan, upper left) and Betaproteobacteria (blue, lower right); 
b, Alphaproteobacteria (cyan); c, Firmicutes (purple); d, Firmicutes (with very long 
sequences, red); e, Bacteroidetes (yellow); f, Actinobacteria (orange); g, Cyanobacteria 
and plants (green); h, Apicomplexa (pink, genus Plasmodium, the malaria parasites) and 
i, Desulfobacterales (brown, an order of Deltaproteobacteria). j, the architectures of IspH-
RPS1 with 4 (top) and 6 (bottom) S1 repeats; k, the architectures of IspH-UbiA. 
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Figure 2.2 Sequence similarity network of IspH-RPS1 cluster, expectation-value (e-
value) of 10-160. Blue: Clostridia. Orange: Negativicutes. Green: Thermotogae. Red: 
Fusobacteria. Circle: IspH-RPS1 with 6 S1 repeats. 
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Figure 2.3 Other IspH fusion proteins found from the sequence similarity network. (a) 
CMP-IspH-RPS1 from Candidatus Arthromitus SFB-X (X=1, 2, 3, 4, 5, mouse-NL, and 
rat). (b) IspH-helicase, from Bacteroidales bacterium CF. (c) FBP-IspH from Chromera 
velia. (d) UDP-IspH from Frankia sp. (QA3., EUN1f., and strain EAN1pec). (e) IspH with 
an N-terminal conserved domain, from photosynthetic organisms. 
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Figure 2.4 The UbiA superfamily. The UbiA superfamily has a very diverse range of 
substrates for prenylation and the substrates/products in several cases are not known. 
The sub-groups of UbiA and their substrates are listed. Atoms in red indicate the sites of 
prenylation. The UbiA in the IspH-UbiA hybrid belongs to the UbiA_5 category with 
unknown function.  
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Figure 2.5 IspH structures and IspH-fusion protein structure predictions. (a) X-ray 
structure of E. coli IspH (PDB ID code: 3KE8). (b) X-ray structure of P. falciparum IspH 
(PDB code: 4N7B). (c) Phyre2 structure prediction of CthIspH-RPS1. The IspH domains 
are in orange while the 4 S1 repeats are colored green, purple, blue, or cyan. (d) Phyre2 
stucture prediction of Desulfobacula toluolica IspH-UbiA. Orange: IspH domain. Blue: 
UbiA domain. Green: X-ray structure of Aeropyrum pernix UbiA (PDB ID code: 4OD5) 
Yellow spheres: conserved Cys in IspH. Purple spheres: conserved Asp in UbiA domain in 
IspH-UbiA. 
 
 
42 
 
 
Figure 2.6 Characterization of CthIspH-RPS1 and its truncation mutants. (a) MALDI-
TOF spectrum of purified CthIspH. M1: CthIspH-RPS1; M2: EcRho, see Text for more 
details. (b) UV-Vis spectrum of CthIspH-RPS1 after iron-sulfur cluster reconstitution 
(black) and after dithionite reduction (red). (c) Michaelis-Menten kinetics of CthIspH-
RPS1. (d) Cartoon of the truncation proteins. D0: no S1 repeat, D1: one S1 repeat, D2: two 
S1 repeats, D3: three S1 repeats. WT has the four S1 repeats. (e) Relative activities of 
truncation mutants compared to wild-type protein. Error bars are from n=3 replicates. (f) 
EPR of reduced CthIspH-RPS1, its truncation mutants, and E. coli IspH. (g) EPR of 
CthIspH-RPS1_1-171, reduced protein, with substrate HMBPP (1) and several ligands. 
The small peak at g=2.0 in the oxidized protein sample (blue) is due to the small amount 
of [Fe3S4]+ . 
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Figure 2.7 LC-MS of CthIspH-RPS1 catalyzed reaction confirmed the production of 
DMAPP/IPP and consumption of HMBPP. DMAPP and IPP were not separated in this 
chromatogram. 
 
 
 
Figure 2.8 Simulation of the g=5.0 signal from the EPR spectrum of reduced CthIspH-
RPS1 with an S=7/2 spin system and E/D=0.117. The total effective g-values are listed. 
Simulation was carried out using Visual RHOMBO (http://www.tnw.tudelft.nl/nl/over-
faculteit/afdelingen/biotechnology/data-software/visual-rhombo/). 
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Figure 2.9 Inhibition of CthIspH-RPS1. (a) Compounds tested in the CthIspH-RPS1 
inhibition assays and their IC50 values against CthIspH-RPS1 (top) and AaIspH (bottom). 
(b) Dose-response inhibition curves of three acetylene inhibitors. (c) 9 GHz EPR spectra 
of CthIspH-RPS1 reduced without ligand, reduced + 4, reduced +8, and reduced + 13. 
 
Figure 2.10 (A) E. coli Rho transcription termination factor MS fingerprint. Covered 
peptide fragments are shown in red. (B) SDS-PAGE gel showing that EcRho can be 
dissociated from IspH-RPS1 with a (CT)4 DNA oligomer.  
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Figure 2.11 The growth curve of E coli BL21(DE3) cells harboring different IspH-RPS1 
constructs. 
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Figure 2.12 Possible IspH-RPS1/RelA/Rho ribosome interactions. Upon binding to the 
ribosome through the RPS1 domain, IspH could interact with RelA and affect its activity. 
The ppGpp released modulates a series of cell activities, for example inhibiting RNA 
polymerase (RNAP). The transcription termination factor Rho could also be affected upon 
interacting with IspH-RPS1 (as suggested from the MALDI-TOF experiments). 
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Chapter III   
Structure and function of four classes of the 4Fe-4S 
protein, IspH 
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3.2 Introduction 
Terpenes constitute the largest family of small molecule natural products and are 
biosynthetically derived from two universal precursors: dimethylallyl diphosphate 
(DMAPP, 1, Scheme 3.1) and isopentenyl diphosphate (IPP, 2, Scheme 3.1).1 In most 
bacteria as well as in plants and apicomplexan parasites, these two C5 building blocks are 
produced via the 2-C-methyl-D-erythritol 4-phosphate (MEP) pathway with both 1 and 
2 being synthesized by the 2H+/2e- reductive dehydroxylation of E-1-hydroxy-2-methyl-
but-2-enyl 4-diphosphate (HMBPP, 3, Scheme 3.1).2 This reaction is catalyzed by the 4Fe-
4S cluster-containing enzyme IspH (also known as LytB—but not to be confused with the 
LytB found in Streptococcus pneumoniae) and due to the essential nature of the MEP 
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pathway for survival—and its absence in humans—IspH is thought to be an attractive drug 
target for infectious diseases such as malaria and tuberculosis,3 as well as a target for 
herbicide development. In addition, HMBPP itself is a very potent "phosphoantigen"4 
targeting γδ T cells (containing the Vγ2Vδ2 T cell receptor) and activated γδ T cells kill 
tumor cells, so IspH inhibitors also have the potential to be novel cancer 
immunotherapeutics.  
IspH is a 4Fe-4S cluster-containing protein in which the cluster is bound (by Fe-S 
bonds) to 3 Cys residues (C13, C96, C197 in E. coli), the unique 4th Fe being directly 
involved in substrate binding and catalysis, and there have been numerous studies of its 
mechanism of action,5 based on which some potent inhibitors have been developed.5-6 
Both experimental and computational studies now generally agree on a reaction 
mechanism involving two consecutive one-electron transfer steps with a HIPIP (high-
potential iron protein)-like [Fe4S4]3+-allyl anion intermediate.5, 7 The X-ray structures of 
IspH from E. coli,8 Aquifex aeolicus9 as well as an N-terminal truncation mutant of  
Plasmodium falciparum10 have been obtained and show a similar "trefoil" arrangement 
of α/β domains with the Fe-S cluster bound at the center of the structure. However, both 
E. coli IspH (EcIspH) and P. falciparum IspH (PfIspH) also contain a C-terminal 
extension that is missing in A. aeolicus IspH (AaIspH), raising the question as to the role 
of this domain. This C-terminal extension is quite long (~25 residues) and appears as a 
"belt" across the proposed electron transfer (ET) surface of the protein, as discussed more 
below. 
It has also been reported that PfIspH can form a relatively stable complex with P. 
falciparum ferredoxin (PfFd),11 and can readily convert HMBPP into DMAPP and IPP 
using reduced PfFd as the electron donor, while AaIspH does not use ferredoxin as 
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efficiently.11 The binding between PfIspH and PfFd was then suggested, based on the 
results of a computational docking investigation, to be mediated by the C-terminal tail 
which was involved in several specific polar interactions that resulted in the 2Fe-2S 
cluster in PfFd being ~13 Å from the 4Fe-4S cluster.10 EcIspH was also able to utilize 
ferredoxin, as well as flavodoxin, as an electron shuttle partner.2b These studies suggest 
that the IspH ET partner binds to one surface of IspH, the surface that contains the belt 
residues. In other studies, AaIspH—which is tail-less—was shown to be catalytically active 
with dithionite, an inorganic reducing agent, but the reaction of EcIspH with dithionite 
was extremely slow.2b In both cases, the reactions were accelerated in the presence of the 
electron mediator methyl viologen, but the origins of these differences in catalytic activity 
have been unclear. 
In our group, we recently discovered that some IspHs from anaerobes form "Rosetta 
stone" hybrids with other proteins12 and the IspH domains in these and many other 
obligate anaerobic bacteria lack the C-terminal tail region seen in EcIspH, suggesting that 
the presence of this region might be related to oxygen tolerance and indeed, IspH is one 
of the few essential proteins in E. coli that are air-sensitive.13 Here, we sought to 
investigate the structure and function of a broad range of IspHs—proteins from anaerobic 
and aerobic bacteria, plants as well as parasitic protozoa—in order to see how different 
organisms might protect their clusters from oxidative damage, in addition to how residues 
on the ET side (as opposed to the substrate-binding side) of the protein might affect 
catalytic activity.  
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3.3 Results and Discussion 
3.3.1 IspH active site structures.  
The X-ray crystallographic structures of three IspHs have been reported8-10 In early 
work, we reported the structure of IspH from the thermophile Aquifex aeolicus.9 Then, 
the structure of the E. coli protein was reported,8 followed later10 by that of the 
Plasmodium falciparum protein (minus its N-terminus). None of these three proteins 
crystallized with intact 4Fe-4S clusters, although these are seen in ligand-bound E. coli 
structures. Three views of the reported structures of each protein are shown in Figure 
3.1A-C. In each case there is the basic "trefoil" arrangement of three α/β domains that 
surround a central Fe-S core. In functional IspHs the (oxidized) cluster is [Fe4S4]2+ which 
is bound to 3 conserved Cys: C13, C96 and C197 (we use the E. coli numbering system 
since most structures have been of this protein). The 4th, unique Fe is involved in ligand 
binding, in catalysis. The results of nuclear resonance vibrational spectroscopy (NRVS) 
indicate that 3 waters bind to this Fe in the oxidized protein.14 This oxidized form of IspH 
is relatively sensitive to oxidants, however, losing one Fe, but is stabilized by ligands such 
as HMBPP, as well as by some inhibitors. The question then arises as to how IspHs might 
in general stabilize their 4Fe-4S cluster. And how might IspHs from different organisms, 
subjected to different oxidative stresses, effect cluster stabilization? In addition: are 
protein residues on the ET side of the protein directly involved in catalysis? 
As can be seen by comparing the A. aeolicus IspH structure (Figure 3.1A; PDB ID 
3DNF)9 with that of E. coli IspH (Figure 3.1B; PDB ID 3KE8)8 and P. falciparum IspH 
(Figure 3.1C; PDB ID 4N7B),10 both EcIspH and PfIspH contain a long (~25 residue) C-
terminal extension. This C-terminal tail, highlighted in green, is above the trefoil plane, 
on the opposite side to the HMBPP substrate-binding pocket, shown in pink in the 
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EcIspH-HMBPP structure (Figure 3.1B), and is also present in the PfIspH structure 
(Figure 3.1C). In space-filling models the C-terminal extension clearly appears as a belt 
or strap across one face of the protein, above the first and third α/β domains. This location 
suggests that the C-terminal tail is not involved in substrate binding but rather, as 
suggested by Rekittke et al.,10 is involved in electron transfer and perhaps, in protecting 
the cluster from oxygen or other reactive oxygen species (ROS) and potentially, reactive 
nitrogen species (RNS). In AaIspH (Figure 3.1A), the Fe-S cluster is relatively solvent 
exposed. Expanded views of the cluster and belt region of both EcIspH-HMBPP and 
PfIspH are shown in Figure 3.1D and 1E and gives clues as to the role of some of the 
residues in this domain. In EcIspH (Figure 3.1D), there are two salt bridges that link the 
belt with the trefoil plane: R296 forms a salt bridge with E205, and E298 with R203. In 
PfIspH, only the latter interaction is present (Figure 3.1E). Note that the Fe-S cluster in 
EcIspH is [4Fe-4S] and that the HMBPP substrate is bound, while in PfIspH the cluster 
is [3Fe-4S], due to loss of one Fe during crystallization.  
What is particularly interesting is that in both structures, there are two aromatic 
amino-acid residues that are very close to the more solvent-exposed side of the cluster—
the proposed ET surface. In EcIspH (PDB ID 3KE8),8 Y198 has 3.8 Å (Cε2-S4), 4.4 Å (OH-
S4) contacts with (or, more accurately, distances to) the cluster, while F302 has two 
longer distances, both at 5 Å (Cε1-S4 and Cζ-S4). The central "core" of all IspHs, as noted 
previously, has three conserved Cys, and Y198 is adjacent the third Cys, C196. So one of 
the aromatic residues is in the trefoil core IspH structure (as found in e.g. AaIspH) while 
the second is in the C-terminus extension. In the PfIspH structure (Figure 3.1E), Y414 
(corresponding to Y198 in EcIspH since PfIspH has an N-terminal plastid-targeting 
domain) has a 3.8 Å (Cε1-S3) distance to the cluster (PDB ID 4N7B)10 while W520 (in the 
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C-terminus extension) has a 4.4 Å (Cη2-S3) contact distance. While these distances are 
long compared to bond distances, they obviously show that in both EcIspH as well as in 
PfIspH, two aromatic amino-acids are close to the clusters, suggesting that in both cases 
they could be involved in electron transfer.10 In addition, these aromatic groups could 
provide steric protection against oxygen or other, reactive oxygen/nitrogen species. In the 
case of AaIspH, the C-terminus extension is absent but there are still two aromatic amino-
acids close to the cluster, F14 and Y98, with cluster distances in the 4.4-4.6 Å range (PDB 
ID 3DNF).9  A superposition of the aromatic groups in all three IspHs near the ET side of 
the cluster is shown in Figure 3.1F. In each of the three proteins there are, therefore, two 
aromatic amino-acids that have cluster distances of, on average, ~4.3 Å. We hypothesize 
that these residues and structural arrangements observed might represent distinct motifs 
in different organisms, tailored perhaps to the oxygen levels (or ROS/RNS) in the 
organism's environment—as well as being involved in ET. 
3.3.2 There are 4 major IspH structural classes.  
We next sought to see how the general structural observations noted above might be 
extended and perhaps generalized to different organisms, to determine if there are 
clearly-defined IspH structural classes. To do this we first carried out a sequence 
alignment15 of a broad range of bacterial, plant and apicomplexan IspHs, Figures 3.2, 3.3. 
The conserved IspH C-terminal tail is mainly found in aerobic bacteria and in 
protozoan parasites, with aerobic bacteria containing a conserved F302 and the 
protozoan parasites, a corresponding W302 (using the EcIspH numbering system). When 
1389 IspHs (all IspHs, with <80% homology, from the database) were aligned, 617 (44%) 
were found to contain the C-terminal domain with conserved Phe or Trp. C-terminal tail-
less IspHs were almost all from anaerobic/microaerophilic bacteria and photosynthetic 
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organisms—cyanobacteria and green plants (Figure 3.2). However, instead of the C-
terminal extension, the IspHs of cyanobacteria and green plants have large N-terminal 
extensions.16 In plants, there is also a plastid targeting sequence (that is not required for 
activity and is absent in the cyanobacteria). Moreover, there is a highly conserved residue, 
Y72* (we use the Arabidopsis thaliana numbering system here to be consistent with the 
literature, the * indicating a different numbering system to that used for the bacteria) in 
the N-terminal domain, Figure 3.3, that is essential for catalytic activity. This Tyr has been 
proposed to be involved, in chloroplasts, in protecting IspH from high oxidative stress.16 
However, since only a computational model of a plant IspH is available,17 it is not possible 
to know whether or not this Tyr residue is close to the 4Fe-4S cluster. Nevertheless, when 
all of the above structural and bioinformatics data is considered, it leads to the conclusion 
that there are actually four major classes of IspH that we shall call Classes A-D. A 
graphical representation of this proposal is shown in Figure 3.4A. 
The simplest structural organization we shall call Class A and is that found in e.g. A. 
aeolicus in which there is just the basic trefoil "core" IspH structure reported earlier 9—
with no N or C-terminal extensions—and the aromatic amino acids are F14, Y98, adjacent 
the 1st and 2nd conserved Cys, Figure 3.2. Class B IspHs are characterized by addition of 
the conserved C-terminal domain (CCD), Figure 3.4, and the aromatics are the core Y198 
(adjacent the 3rd conserved Cys) (Figure 3.2), and Y302, in the CCD domain. Class C 
IspHs are those found in plants and cyanobacteria. They adopt the Class A core structure, 
but lack the CCD, and have instead a conserved N-terminal domain (NCD)16 with a highly 
conserved Y72*. These IspHs are expected to be under great oxidative stress (during 
photosynthesis) and the proposal that the NCD contributes to oxidative stability is an 
attractive one. Class D IspHs are those found in apicomplexan parasites such as P. 
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falciparum, a malaria parasite, Toxoplasma gondii, the causative agent of toxoplasmosis, 
and Babesia bovis, which causes babesiosis. Class D IspHs have the basic Class B 
structure, Y/W198 together with a CCD (F302 or W302), plus, there is also an NCD, just 
as found in plants, in addition to a plastid (apicoplast) targeting domain. As can be seen 
in the structural alignment in Figure 3.3, the highly conserved Y72* seen in plants is also 
present (as Y or W) in the apicomplexan parasites, which are also expected to be under 
oxidative stress (ROS/RNS) when inside mammalian host cells.  
In earlier work12 we reported using a Cytoscape analysis18 that there were ~9 different 
IspH clusters, based purely on amino-acid sequences. However, essentially all (96%) of 
these IspHs are now seen to belong to one of the four "superclasses" discussed above, as 
shown in Figure 3.4B (gold=Class A; blue=Class B; green=Class C and red=Class D). The 
exception is the grey cluster iii (4%) comprised of firmicutes, mostly Bacillus and 
Geobacillus spp. which have just 1 aromatic residue (Y14) near the cluster, and a CCD 
without aromatic residues.  
The results described above indicate, then, that there are 4 major classes of IspH that 
can be distinguished based on the presence of aromatic amino-acid side-chains near the 
[4Fe-4S] cluster; the presence or absence of a C-terminal extension (containing an 
aromatic amino-acid near the cluster); and/or an N-terminal extension (with a highly 
conserved Y72*).  We thus next sought to see how mutations of some of the putative key 
residues discussed above, known to be located near the 4Fe-4S clusters, might affect 
catalytic activity, as well as oxidative stability, since it appeared that these Phe/Tyr/Trp 
residues could be involved in ET activity (they are located near the cluster, on the ET side 
of the protein) and in their absence, the clusters appeared to be relatively solvent exposed. 
Since, to date, there are no structures of complete Class C or Class D proteins (i.e. with 
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the C/N-terminal domains), we focused on the Class A and B proteins, and in Class B, the 
C-terminal chain extension, the CCD. So, only the NCD was not investigated, and indeed 
studies of the complete NCD in plants will be challenging since the intact proteins are 
expected to target plastid membranes and to date, none have been successfully expressed 
and isolated—yet alone crystallized—although the cyanobacterial IspHs may be more 
tractable. 
3.3.3 IspH tail and aromatic residues can affect IspH catalytic activity.  
We first investigated the cluster-associated residues in EcIspH since EcIspH is the only 
IspH that has known structures containing intact 4Fe-4S clusters, and ligands. We made 
three mutants: a "truncation mutant" Ec291 containing only residues 1-291, i.e. without 
the C-terminal tail (residues 292-316); EcF302A, with the mutation in the CCD, and 
EcY198A, in which the mutation is near the third conserved Cys that binds to the 4Fe-4S 
cluster. All EcIspHs were produced with the 4Fe-4S cluster bound by co-expressing IspH 
with an isc expression system (for cluster insertion), and had a dark brown coloration and 
an Fe content that was very similar to that we find with wild-type IspH, Table 1. We then 
determined the kinetic behavior of the three mutants by using a methyl viologen-based 
assay,2a Figure 3.5. In this assay, Figure 3.5A, HMBPP reduction is determined 
spectrophotometrically via the oxidation of the methyl viologen radical. kcat and Km values 
derived from Figure 3.5A are given in Table 1. The activity of Ec291 was significantly 
diminished as compared to wild-type IspH, with only ~7% activity found. EcF302A also 
exhibited low activity, ~30% that of the wild-type enzyme, but EcY198A was just as active 
as wild-type. The loss of activity was mainly due to a significant decrease in kcat, while Km 
changed by less than a factor of two. This Km observation was not unexpected since none 
of the mutations were close to the substrate binding site, Figure 3.1. We then investigated 
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the HMBPP reduction kinetics of these three mutants using this time, dithionite as the 
reducing agent and an HPLC-based end-point assay to measure the time course of the 
reaction, Figure 3.5B. The initial conversion rates, kDT, derived from Figure 3.5B, are 
shown in Table 1.  In contrast to the results obtained in Figure 3.5A, Ec291 exhibited a 
much faster (~10-fold) kDT than did wild-type IspH. Moreover, EcF302A was ~5-fold 
more active than was wild-type, and EcY198A had about the same activity as wild-type. 
These results, while surprising, are consistent with the report that "tail-less" AaIspH 
converts HMBPP using dithionite at a faster rate than does EcIspH.2b And since the 
mutants did not change the Km of IspH significantly, the changes in catalytic activity 
seemed likely to originate from differences in the ET rates. We thus next investigated the 
ET rates using a stopped-flow technique, and correlated the results with other kinetic 
properties.  
Dithionite uses the [SO2-] radical as the (one-electron) reductant with the following 
mechanism and kinetics:19 
S2O42-
𝐾1
⇔2SO2- 
SO2-+E (ox) 
𝑘2
→SO2+E (red) 
v=k2 [E] [SO2-] = kobs [E]; kobs = k2 [SO2-] =k2K10.5[S2O42-]0.5 
The pseudo-first order rate constants, kobs, from the reactions between IspH and excess 
dithionite were measured by monitoring the decrease of the absorbance of the oxidized 
4Fe-4S cluster at 415 nm. The second-order kinetic constants, k2, were then determined 
by plotting kobs against the square root of the dithionite concentration and dividing the 
slope of this plot by the square root of the dissociation constant of dithionite, K1. As shown 
in Figure 3.5C and Table 1, the reaction rate between Ec291 and dithionite was > 5x faster 
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than with wild-type IspH, and the ET rate for the EcF302A mutant was 3x faster than 
wild-type, with EcY198A again having about the same reaction rate as with wild-type 
protein. These results indicate that removing the tail region of EcIspH increases the ET 
rate between the enzyme and dithionite. Moreover, these k2 ET rate results correlate 
(Figure 3.6A) with the catalytic activity results kDT, Figure 3.5B, using dithionite as the 
reducing agent, indicating that the differences in the ET rates are the basis for the 
correlation observed. The observed ET rates (kobs) were, however, ~3x smaller than the 
overall reaction rates (kDT) at the same dithionite concentration, Figure 3.5B, C and Table 
1. This observation is surprising, but a possible explanation is that in the ET experiments 
(kobs), the Fe4S4 cluster is bound to three waters 14 but in actual catalysis (kDT), the Fe4S4 
cluster is bound to the substrate, which can stabilize the cluster. The ΔG for the ET 
reaction may thus be lower in the latter case, resulting in an increased rate of the ET 
reaction.20 
There is also an interesting anti-correlation between k2 and kcat using methyl viologen, 
Figure 3.6B. The fact that tail-less EcIspH was reduced more rapidly by dithionite than 
was wild-type IspH, but more slowly than wild-type with methyl viologen, is again 
surprising. However, a likely explanation is that since dithionite (or [SO2-]) is a very small 
species, it can very readily react with the cluster when the IspH tail region of IspH is 
removed and the Fe-S cluster is solvent exposed. The methyl viologen radical cation is, 
however, much larger and more hydrophobic than [SO2-], and ET may require an ET 
mediator on the IspH tail—one of the aromatic amino-acids—to facilitate binding and 
electron transfer. Such a process would be similar to the reaction that occurs inside cells, 
where the C-terminal tail has been proposed to be critical for binding (or reaction) 
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between ferredoxin and PfIspH.10 Such an exposure of the cluster would also be expected 
to affect cluster stability, as discussed below. 
3.3.4 The IspH tail and aromatic residues affect IspH stability towards 
oxygen/reactive oxygen species.  
Since the tail-less EcIspH reacted with dithionite more rapidly than did the wild-type 
protein, it seemed likely that other small molecules, such as oxygen and other reactive 
oxygen (or nitrogen) species would also have ready access to the cluster, resulting in 
cluster degradation. That is, the presence of the CCD or other cluster-associated 
aromatics might be expected to enhance IspH stability, under oxidizing conditions. We 
therefore tested the stability of wild-type and mutant IspHs upon exposure to air. All wild-
type as well as IspH mutants were stable for months inside a glovebox without significant 
loss of Fe-S cluster content. However, upon exposure to air, mutant stability decreased, 
Figures 3.7 and 3.8. Without any "exogenous" cluster ligand present (endogenous water 
is assumed), the cluster in Ec291 degraded very rapidly and there was some protein 
precipitation, while wild-type and the two EcIspH point mutants reacted at similar rates 
(Figure 3.7A). In the presence of the HMBPP (3) substrate, however, the stability of the 
wild-type enzyme increased and a significant amount of [4Fe-4S] cluster was still present 
even after a 12 hr exposure to air (Figures 3.7B, C). The EcY198A and EcF302A mutants 
had intermediate stability while Ec291 degraded just as rapidly as with the unliganded 
protein. The stability of the different IspHs correlated with their reactivity with dithionite, 
Figure 3.6C, as anticipated. We then carried out a second set of experiments with a second 
ligand 4 that we previously found enhanced cluster stability, as well as with 3 and 4 in 
the presence of 100 µM H2O2, Figure 3.7C and Figure 3.8. Similar results were obtained 
in the H2O2 exposure experiments to those obtained with oxygen exposure. Thus, addition 
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of 3 or 4 increases cluster stability and this can be attributed to these ligands binding to 
the unique, 4th Fe in the cluster, preventing attack—from the substrate side—by ROS. 
However, oxygen and ROS can still attack from the "top" or ET side of the cluster, and 
here we see a difference in stability between the mutants with stability increasing from 
Ec291 to EcF302A to EcY198A to wild-type, with F302 playing the major role in cluster 
protection, Figures 3.7B, C. 
These results and those of our EPR studies (discussed more below) indicate that the 
HMBPP (3) and 4 ligands can bind to Ec291 just as they do to wild-type IspH. However, 
the Fe-S cluster in Ec291 is more susceptible to attack by oxygen because the cluster is 
more solvent exposed, while in wild-type IspH, the cluster is protected by the C-terminal 
tail as well as by Y198. As noted above, all apicomplexan parasites have a conserved Trp 
instead of a Phe in their CCD tail region due, we propose, to the fact that these parasites 
reside inside mammalian cell where oxidative stress from ROS (and RNS) is likely to be 
very high, and the larger Trp may provide an increased steric barrier against attack by 
these species. Taken together with the kinetic results, it thus appears that the CCD and 
aromatic residues near the 4Fe-4S cluster (both F302 and Y198) significantly affect 
cluster stability, and in the case of F302, catalytic activity. The question then arises as to 
whether such aromatic residues affect activity and stability of the naturally “tail-less” 
Class A IspHs. 
3.3.5 Effects of cluster-associated aromatic residues in AaIspH.  
AaIspH, from Aquifex aeolicus, contains F14 and Y98 near the 4Fe-4S cluster, Figure 
3.1, so we prepared AaF14A and Y98A mutants. The catalytic activity of AaIspH and its 
mutants were measured as described above, with methyl viologen radical or dithionite as 
the reducing agents. As shown in Table 1 and Figure 3.9, the mutations have similar 
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effects in both dithionite and methyl viologen assays: AaY98A ~2.2x and AaF14A ~1.6x 
faster than wild-type. Both sets of kinetics results correlate well with the ET rates between 
the AaIspHs and dithionite, Figures 3.10A, B, in which we plot kcat or kDT for AaIspH 
catalysis against the ET rate constant (k2) of the AaIspHs. The small increase in reactivity 
of AaY98A and AaF14A with dithionite can be explained by a steric effect, as we proposed 
for EcIspHs. Notably, with wild-type AaIspH, the conversion rate of the enzyme using the 
methyl viologen radical as the reducing agent was only ~3x larger than when using 
dithionite, Table 1, while with wild-type EcIspH, methyl viologen was >100x more 
efficient than was dithionite, and with Ec291, methyl viologen was less efficient than 
dithionite: these results again indicate a critical role for the C-terminal domain in EcIspH 
in transferring electrons between the methyl viologen radical and the Fe-S cluster.  
In contrast to these relatively small effects on catalytic activity, F14 and Y98 in AaIspH 
have major effects on cluster stability with respect to oxygen/ROS. In the absence of any 
exogenous ligand, AaIspH and the two mutants decomposed in air at similar rates, Figure 
3.11A, rates that were larger than with the E. coli homologs (which contain the tail). The 
presence of HMBPP (3) improved the stability of all AaIspHs, Figure 3.11B, and the decay 
rates were more similar to those of EcIspH and were also well-correlated with the ET rates 
measure with dithionite, Figure 3.10C. The effect of nearby aromatic residues on Fe-S 
cluster stability have also been observed in other 4Fe-4S systems. In a HIPIP ferrodoxin 
21, a Tyr residue in close proximity to the 4Fe-4S cluster was demonstrated to stabilize the 
cluster upon exposure to air, and the redox potential of the 4Fe-4S cluster was not affected 
by mutating the Tyr. Instead, steric effects were proposed to be the main reason for the 
differences in stability, as we propose here for IspH. 
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Interestingly, the 4Fe-4S cluster protein IspG (GcpE) is even less stable to oxidants 
than is IspH.22 This protein functions as a dimer and each monomer has 2 domains: a 
4Fe-4S domain that binds to O3 in the 2-C-methyl-D-erythritol-2,4-cyclo-diphosphate 
(MEcPP) substrate, and a TIM barrel domain that binds to the MEcPP diphosphate. The 
structure exhibits a hinge-bend motion and in the open form (that is, in the absence of 
substrate/intermediate/product/inhibitor ligands) the cluster is rapidly degraded by 
oxygen, and in cells by methyl viologen which generates ROS,23 this instability arising we 
propose from the lack of any nearby aromatics in the 4Fe-4S cluster, unlike the situation 
with IspH.  
3.3.6 Aromatic residues affect the [electronic] structure of the [4Fe-4S] 
cluster.  
In order to investigate possible interactions between the [4Fe-4S] cluster and ET-side 
residues in IspH, we obtained EPR spectra of each of the IspHs. It is important to note 
that, to date, there have been no reported IspH X-ray structures containing intact 4Fe-4S 
clusters, oxidized or reduced, in the absence of exogenous ligands, although NRVS 14 
indicates 3 waters bind to the oxidized protein—consistent with previous Mössbauer 
results.24 As shown in Figure 3.12A and Table 2, reduced wild-type EcIspH exhibits an 
axial (9 GHz) EPR spectrum with g values of [2.025, 1.899, 1.876] and a Δg of 0.149. In 
the case of Ec291 in which F302 (and other) residues are absent, the spectrum is rhombic, 
with g values of [2.007, 1.907, 1.797] and a Δg of 0.21. The rhombic spectrum has a line 
shape that is similar to that of a [2Fe-2S] cluster,25 although the possibility that the signal 
actually arises from such a species seems remote given that all spectra were taken at 10 K; 
the mutants had similar iron contents as did wild-type, and the acetylene inhibitor 4 
bound to all four reduced IspHs. The Ec291 EPR spectrum shows that at least one residue 
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post-291, in the tail, must be responsible for the differences between the spectra of wild-
type IspH and the Ec291 mutant, but does not indicate which residue/residues are 
responsible. However, since the spectrum of reduced EcF302A is also different to wild-
type and is very similar to that of Ec291, the spectroscopic differences between wild-type 
EcIspH, Ec291 and EcF302A must be due, at least in part, to the presence of F302 in the 
wild-type protein (otherwise the wild-type and EcF302A spectra would be the same). The 
spectrum of reduced EcY198A is also very similar to that of EcF302A and Ec291, but not 
wild-type, meaning that both of the aromatic amino-acid residues that are close to the 
[4Fe-4S] cluster can have similar effects on the structure of the Fe4S4 clusters that result 
in the spectral changes observed.  After binding to compound 4, however, the spectra of 
all four systems are essentially the same and are characteristic of typical π-ligated 4Fe-4S 
clusters, Figure 3.12B, reported previously.26 Whether the spectral changes that are seen 
in the ligand-free proteins are due to a direct cluster interaction with the aromatic rings 
or a more indirect, protein-mediated effect, or changes in water ligation, is not known, 
but in either case, it is of interest that there are in fact aromatic ring effects on cluster 
structure, with both aromatic residues stabilizing the EcIspH cluster from ROS.  
In the case of AaIspH, the effects of mutating the aromatic residues to AaF14A and 
AaY98 were quite small, Figure 3.12C, Table 2. In the absence of any exogenous ligand, 
lineshapes and g-values were very similar with g values of [2.022, 1.903, 1.842; AaIspH], 
[2.023, 1.904, 1.856; AaF14A] and [2.021, 1.898, 1.849; AaY98A], Figure 3.12C. The only 
differences were very slight changes in g3 and a line broadening of g3 that gave AaY98A a 
more axial lineshape. The broadening was more obvious in the ligand-bound spectra, 
Figure 3.12D, leading to a slightly different lineshape for AaF14A and AaY98A, although 
their g values were identical to wild-type, [2.097, 2.014, 1.997]. The line-broadening is 
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likely caused by a larger g-strain, due perhaps to increased heterogeneity in protein 
conformations caused by the mutations. In addition, AaY98A exhibited a larger signal for 
a higher spin species, at g~5, as compared to AaIspH wild-type and AaF14A. The g~5 
signal is likely due to an S=7/2 species, as suggested previously.12 The EPR results show, 
therefore, that there are clear differences between the Class A (AaIspH) and Class B 
(EcIspH) proteins. In the Class B protein EcIspH there are interactions between F302 
and the 4Fe-4S cluster that result in changes in cluster structure, consistent with a role 
for these residues in ET and catalysis where, as can be seen in Table 1, the difference in 
kcat/Km between wild-type EcIspH and Ec302A is large. In contrast, the differences 
between the kcat/Km values for AaIspH and its mutants are all small, Table 1, consistent 
with the lack of significant differences in their EPR spectra, Figure 3.12. However, in both 
the Class A and Class B protein, the aromatics provide cluster protection from O2 and 
other reactive oxygen species. 
 
3.4 Conclusion 
IspH is an important drug target for many diseases, as well as an herbicide target. Here, 
we discovered that there are actually four IspH classes, each of which have the side-chains 
of two aromatic amino-acids in close proximity to the 4Fe-4S cluster, but on the opposite 
side of the cluster to that involved in substrate binding and the reductive dehydroxylation 
reaction: "the ET side" of the protein that interacts with ferredoxin/flavodoxin and other 
reductants. Class A IspHs are found primarily in anaerobic/microaerophilic bacteria and 
have F14, Y98 close to the 4Fe-4S cluster. Class B are found in most aerobic bacteria and 
have Y198 together with F302 close to the cluster, with F302 being located in a conserved 
C-terminal extension. Class C are found in green plants and cyanobacteria and contain 
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the Class A motif, in addition to incorporating an N-terminal domain. Class D are found 
in apicomplexan parasites and contain the Class B motif with its C-terminal extension, 
together with the N-terminal domain found in plants. The results of site-directed 
mutagenesis show that the aromatic groups protect the 4Fe-4S clusters from oxidative 
damage as well affecting electron transfer rates and catalytic activity, and the 
bioinformatics and structural results taken together indicate that organisms that are 
expected to experience the highest levels of oxidative stress (plants and intracellular, 
apicomplexan parasites) are likely to have the largest aromatic residue (Trp) close to the 
cluster, as well as N-terminal (plant) or N-terminal plus C-terminal (apicomplexan) 
extensions, that provide cluster protection from reactive oxygen species. Overall, the 
results are significant because they provide intriguing new insights into the structure and 
function of an important class of proteins that are both drug as well as herbicide targets 
and suggest the desirability of developing new inhibitors that target the ET surface of the 
protein.  
 
3.5 Materials and Methods 
3.5.1 General.  
All chemicals were purchased from Sigma-Aldrich (Milwaukee, WI) unless otherwise 
indicated. Primers were synthesized by Integrated DNA Technologies (Coralville, IA). 
Restriction enzymes were from New England Biolabs (Beverly, MA). DNA purification 
kits were from Qiagen (Valencia, CA). LC-MS analyses were performed at the 
Metabolomics Center at the University of Illinois, Urbana-Champaign.  
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3.5.2 Purification of EcIspHs.  
E. coli IspH and truncation mutant Ec291were cloned from E. coli strain K-12 into the 
pET-28a (+) (Novagen, WI) vector. EcF302A and EcY198A mutants were generated with 
a QuickChange site-directed mutagenesis kit (Agilent, CA). Sequence-verified plasmids 
containing the corresponding IspHs were co-transformed into E. coli BL21 (DE3) 
(Novagen, WI) together with an isc expression system-encoding plasmid (for 4Fe-4S 
cluster incorporation). For protein production, recombinant E. coli BL21 (DE3) cells were 
grown in 3 liters of LB media at 37 oC. Cells were induced by adding 100 mg/L cysteine, 1 
g/L arabinose and 0.1 mM FeCl3 at an OD600=0.5 for isc expression, followed by 1 mM 
isopropyl β-D-1-thiogalactopyranoside (IPTG) at OD600=0.8, for IspH expression. 
Expression was continued at 25 oC for 24 hrs. Cells were then harvested and frozen at -80 
oC. Purification of wild-type and mutant IspHs was performed at 4 oC in an anaerobic 
chamber (Coy Lab, Grass Lake, MI) with an O2 level < 1 ppm. Briefly, cell pellets were 
suspended in 30 mL of pH 8.0, 150 mM NaCl, 50 mM Tris/HCl buffer containing 
benzonase, protease inhibitor, and 2 mg/mL lysozyme. The suspension was sonicated, 
then centrifuged to remove cell debris. The clear cell lysate was loaded onto a gravity 
column containing 3 mL of HispurTM Ni-NTA resin (Thermo Fisher Scientific, NY), 
followed by washing with 50 mL of pH 8.0, 150 mM NaCl, 50 mM Tris/HCl, 35 mM 
imidazole buffer. His-tagged IspH was eluted using 20 mL of pH 8.0, 150 mM NaCl, 
50mM Tris/HCl, 250 mM imidazole buffer. The elute was then concentrated and desalted 
by using a PD-10 column (Agilent, CA). 
3.5.3 Purification and reconstitution of AaIspH.  
AaIspH mutants AaF14A and AaY98A were cloned from an AaIspH-containing pQE60 
plasmid (modified to harbor a Tet induction system)2a with the QuickChange site-directed 
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mutagenesis kit. Recombinant E. coli BL21(DE3) cells were grown in 2 liters of LB media 
and induced with 200 µM anhydrotetracycline at an OD600 =0.8. Expression was 
continued at 25 oC for 24 hrs. Cells were then harvested and frozen at -80 oC. Purification 
of AaIspHs were the same as for the EcIspHs. However, since Fe4S4 cluster incorporation 
into AaIspHs was less efficient than with EcIspH, we used the cluster reconstitution steps 
for AaIspHs that we described previously.12 
3.5.4 Enzyme kinetics.  
All kinetic assays were performed in an anaerobic chamber with O2 levels < 1 ppm. For 
enzyme kinetics assays using the methyl viologen radical cation as the reducing agent, 1 
mL reaction mixture containing 50 nM IspH, 80 µM sodium dithionite, 1 mM methyl 
viologen and HMBPP (0-70 µM) was incubated at 26 oC. The absorbance of the reaction 
mixture at 606 nm was monitored over a period of 2 min in order to follow the 
disappearance of the methyl viologen radical cation. Km and kcat were derived from the 
Michaelis–Menten equation by using OriginPro 2015 software (OriginLab, Northampton, 
MA). For enzyme kinetics assays using dithionite as the reducing agent, 100 µL of reaction 
mixtures containing 5 µM EcIspH or 3 µM AaIspH, 0.75 mM HMBPP and 3 mM 
dithionite were incubated at room temperature and quenched at 3, 10 or 30 min by adding 
100 µL acetonitrile. The mixtures were centrifuged to remove any precipitates and then 
analyzed by LC-MS. HPLC conditions were as follows: flow rate, 250 µL/min; gradient, 
25 mM NH4HCO3, 20 mM N, N-dimethylhexylamine (DMHA, ion-pairing agent), pH=7.5 
to 80% MeOH, 2 mM DMHA. 
3.5.5 Electron transfer rate.  
Electron transfer rates between the IspHs and dithionite were measured by using the 
stopped-flow technique with an Applied Photophysics (Beverly, MA) model SX20 
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spectrometer. A final concentration of 40 µM IspH and dithionite at 0.5 mM, 1 mM, 2 
mM or 3 mM were mixed in a 20 µL chamber. The reaction was monitored over a period 
of 5 min for EcIspHs or 10 s for AaIspHs. The ET reaction rate, as indicated by the 
disappearance of absorption at 415 nm for the [Fe4S4]2+ cluster, was fitted by using first-
order kinetics, and the pseudo-first-order rate constants were plotted against 
[dithionite]0.5 to obtain the second order rate constants. The equilibrium constant for 
dissociation of S2O42- (K1) was taken to be 1.4×10-9 M.19 
3.5.6 Iron content measurement.  
The iron contents of all IspHs were measured by using a phenanthroline colorimetric 
method as described elsewhere.27 The proteins were desalted to remove any adventitious 
iron present, prior to analysis. 
3.5.7 IspH stability.  
200 µL solutions (50 mM Tris/HCl, 150 mM NaCl, pH=7.5) containing 40 µM IspH, 
with or without 400 µM of ligand (3 or 4)12 were incubated in air at room temperature 
(22 oC). The absorbance of the 4Fe-4S cluster at 415 nm was monitored over 10 hrs. A 
similar set of experiments were also performed in the presence of 100 µM H2O2. In 
addition, we used a qualitative plate assay in order to illustrate the loss of the brown color 
associated with cluster degradation. 
3.5.8 Electron paramagnetic resonance.  
All samples were prepared in an anaerobic chamber with an O2 level <1 ppm. 20% 
glycerol was added to all samples as a glassing agent. Mixtures of 0.3 mM IspH (mutant 
or wild-type), 6 mM dithionite and in some cases, 3 mM 4, were incubated for 15 min and 
then frozen in liquid nitrogen. CW-EPR experiments were performed at X-band (9 GHz) 
using a Varian E-122 spectrometer with an Air Products (Allentown, PA) liquid helium 
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cryostat. Typical parameters for EPR experiments were as follows: temperature, 10 K; 
power, 1 mW; modulation amplitude, 0.5 mT; scan field: 335±80 mT. 
3.5.9 Sequence similarity network.  
The sequence similarity network for the IspH family proteins was that we generated 
previously,12 and is colorized here to indicate the Class A, B, C and D IspHs. 
 
3.6 Schemes, Figures and Tables 
 
 
 
Scheme 3.1 IspH substrate (3), products (1, 2) and inhibitor (4).  
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Figure 3.1 IspH structures. (A) X-ray structure and space filling model of AaIspH (PDB 
ID 3DNF). (B) X-ray structure and space filling model of EcIspH bound to substrate 
HMBPP (3) (PDB ID 3KE8). (C) X-ray structure and space filling model of PfIspH 
(without the N-terminal domain; PDB ID 4N7B). (D) EcIspH tail region. R296 and E298, 
in green, form salt bridges with E205 and R203, respectively. F302, in cyan, and  Y198, 
in yellow are the two aromatic residues near the Fe-S cluster. (E) PfIspH tail region. E515, 
in green, forms a salt bridge with R419. W520, in pink, and Y414, in yellow, are the two 
aromatic residues near the Fe-S cluster (that correspond to Y198 and F302 in EcIspH) . 
(F) Alignment of the Fe-S cluster regions in three IspHs, with the aromatic residues near 
the clusters highlighted. Shown in cyan are Y198 and F302 from EcIspH, light blue are 
F14 and Y98 from AaIspH and purple are Y414 and W520 from PfIspH. Green ribbons in 
the cartoons and space-filling models indicate the C-terminal region. Pink spheres: 
HMBPP. Yellow/orange spheres: Fe-S cluster. 
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Figure 3.2 
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Figure 3.2 (cont.) Multiple sequence alignment of IspHs from different species 
showing the aromatic residues near the Fe-S cluster. Sequence alignment was performed 
with Multiple Sequence Comparison by Log-Expectation (MUSCLE, 
http://www.ebi.ac.uk/Tools/msa/muscle/). Full names of the organisms are as follow: B. 
anthracis: Bacillus anthracis; L. monocytogenes: Listeria monocytogenes; L. 
interrogans: Leptospira interrogans; A. israelii: Actinomyces israelii; S. coelicolor: 
Streptomyces coelicolor; M. tuberculosis: Mycobacteria tuberculosis; N. asteroides: 
Nocadia asteroids; F. tularensis: Francisella tularensis; N. gonorrhoeae: Neisseria 
gonorrhoeae; P. aeruginosa: Pseudomonas aeruginosa; V. chloerae: Vibrio chloerae; H. 
influenzae: Haemophilus influenzae; S. sonnei: Shigella sonnei; S. typhi: Salmonella 
typhi; K. pneumoniae: Klebsiella pneumoniae; C. trachomatis: Chlamydia trachomatis; 
T. gondii: Toxoplasma gondii; P. falciparum: Plasmodium falciparum; P. vivax: 
Plasmodium vivax; B. bovis: Babesia bovis; T. parva: Theileria parva; C. tepdium: 
Chlorobium tepidum; B. fragilis: Bacteroides fragilis; P. gingivalis: Porphyromonas 
gingivalis; T. pseudonana: Thalassiosira pseudonana; A. thaliana: Arabidopsis 
thaliana; G. biloba: Gingko biloba; C. sativus: Cucumis sativus (cucumber);  Z. mays: 
Zea mays (corn); O. sativa: Oryza sativa (rice); D. vulgaris: Desulfovibrio vulgaris; F. 
necrophorum: Fusobacterium necrophorum; H. pylori: Helicobacter pylori; A. aeolicus: 
Aquifex aeolicus; C. perfringens: Clostridium perfringens; P. anaerobius: 
Peptostreptococcus anaerobius; P. difficile: Peptoclostridium difficile. 
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Figure 3.3 Multiple sequence alignment of the N-terminal regions of photosynthetic 
organisms and protozoan parasites. The N-terminal conserved domain and the crucial 
Tyr residue (Y72*) are highlighted.  
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Figure 3.3 (cont.) C. sativus: Cucumis sativus (cucumber); A. thaliana: Arabidopsis 
thaliana; Z. mays: Zea mays (corn); M. acuminata: Musa acuminata (wild banana) G. 
biloba: Gingko biloba; O. sativa: Oryza sativa (rice); M. aeruginosa: Microcystis 
aeruginosa; P. marinus: Prochlorococcus marinus; C. variabilis: Cyanobacterium 
variabilis; C. meralae: Cyanidioschyzon merolae (red alga) T. pseudonana: 
Thalassiosira pseudonana.  
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Figure 3.4 Four classes of IspH. (A) A schematic illurstration of different IspH classes 
based on the nature of the aromatic amino-acids near the 4Fe-4S cluster and the  presence 
or absence of conserved N-terminal (NCD) and C-terminal (CCD) extension domains. (B) 
The sequence similarity network of IspH family proteins showing the distribution of 
different classes of IspHs among various species. Major organism clusters are: (i) 
gammaproteobacteria; (ii) alphaproteobacteria; (iii) firmicutes; (iv) firmicutes; (v) 
bacteroidetes;  (vi) actinobacteria; (vii) cyanobacteria and plants; (viii) apicomplexa and 
(ix) desulfobacterales (an order of deltaproteobacteria). The nine clusters are those 
reported12 and are colored here as gold=Class A; blue=Class B; green=Class C and 
pink=Class D.  
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Figure 3.5 Kinetic properties of EcIspH wild-type and mutant proteins used. (A) 
Michaelis–Menten plots of HMBPP reduction using methyl viologen radical as the 
electron donor for various EcIspHs. (B) Time course of HMBPP reduction by various 
EcIspHs using dithionite as electron donor. 100% conversion corresponds to 150 
turnovers. (C) Plot of kobs against [dithionite]0.5 used to calculate the second order reaction 
rate constant for electron transfer reaction between EcIspHs and dithionite. 
 
 
 
Figure 3.6 Correlations between the ET rate and other kinetic measurements in EcIspHs. 
(A) Correlation between ET rate, k2, (Table 1), of EcIspHs and enzyme activity, kDT (Table 
1) using dithionite as reducing agent. (B) Correlation between k2 of EcIspHs and enzyme 
activity, kcat, (Table 1) using methyl viologen radical as reducing agent. (C) Correlation 
between k2 of EcIspHs and kdecay (Table 1), for enzyme stability.  
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Figure 3.7 Air sensitivity of the 4Fe-4S cluster in EcIspHs under different reaction 
conditions. (A) Fraction of 4Fe-4S cluster in IspHs upon exposure to air. Precipitation in 
Ec291 caused an apparent increase of absorption in the later part of the curve. (B) Same 
as (A), in the presence of a 10-fold excess of HMBPP (3). (C) IspH plate assay: after an 
overnight exposure to air, the brown color of the 4Fe-4S cluster was still present in wild-
type IspH and EcY198A, but not in Ec291 or EcF302A. 
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Figure 3.8 Stability of wild-type and mutant IspHs in the presence/absence of ligands 
and reactive oxygen species. (A), In the presence of a 10-fold excess of compound 4, in 
air; (B), In the presence of 100 µM H2O2; (C), In the presence of a 10-fold excess of 
HMBPP (1) and 100 µM H2O2; and (D), In the presence of a 10-fold excess of compound 
4 and 100 µM H2O2. 
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Figure 3.9 Kinetic properties of AaIspH wild-type and mutant proteins used. (A) 
Michaelis–Menten plots of HMBPP reduction using methyl viologen radical as the 
electron donor for various AaIspHs. (B) Time course of HMBPP reduction by various 
AaIspHs using dithionite as electron donor. 100% conversion corresponds to 250 
turnovers. (C) Plot of kobs against [dithionite]0.5 used to calculate the second order reaction 
rate constant for electron transfer reaction between AaIspHs and dithionite.  
 
 
Figure 3.10 Correlations between the ET rate and other kinetic measurements in 
AaIspHs. (A) Correlation between ET rate, k2, (Table 1), of AaIspHs and enzyme activity, 
kDT (Table 1) using dithionite as reducing agent. (B) Correlation between k2 of AaIspHs 
and enzyme activity, kcat, (Table 1) using methyl viologen radical as reducing agent. (C) 
Correlation between k2 of AaIspHs and kdecay (Table 1), for enzyme stability.  
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Figure 3.11 Air sensitivity of the 4Fe-4S cluster in AaIspHs under different reaction 
conditions. (A) Fraction of 4Fe-4S cluster in IspHs upon exposure to air. Precipitation in 
AaIspH and AaY98A caused an apparent increase of absorption in the later part of the 
curve. (B) Same as (A), in the presence of a 10-fold excess of HMBPP (3).  
 
 
 
Figure 3.12 9 GHz CW-EPR spectra of EcIspH and AaIspH. (A) Spectra of reduced 
EcIspHs without any added ligand. (B) Spectra of reduced EcIspHs with a 10-fold excess 
of compound 4. (C) Spectra of reduced AaIspHs without any added ligand. (D) Spectra of 
reduced AaIspHs with a 10-fold excess of compound 4.  
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Table 3.1 Kinetic parameters and iron contents of the IspHs used in this study. 
 Km, 
µM a 
kcat, 
min-1 a 
kcat/Km, 
min-1µM-1 a 
kDT 
min-1 b 
kobs, 3mM DT 
min-1 c 
k2,[E], [SO2-], 
min-1µM-1 d 
kdecay, 
min-1 e 
[Fe] 
content 
EcIspH 15±3 285±20 16±3 2.3 1.3±0.1 0.86±0.04 3.7 E-4 3.6 
Ec291 23±5 21±2 0.78±0.16 28 6.9±0.2 4.8±0.2 4.0 E-3 3.3 
EcF302A 27±8 83±9 2.6±0.7 9.2 4.0±0.1 2.7±0.1 1.7 E-3 3.4 
EcY198A 17±2 265±10 13±1 3.0 1.5±0.1 0.90±0.05 7.4 E-4 3.6 
AaIspH 2.7±0.8 72±6 23±6 25 38±3 26±1 4.4 E-4 3.6 
AaF14A 3.7±1.1 128±11 29±8 44 67±1 45±2 7.8 E-4 3.7 
AaY98A 3.6±1.3 170±20 40±12 56 82±2 58±3 2.3 E-3 3.5 
a. Measured with methyl viologen as reducing agent at 27°C. b. Initial turnover rates with 
dithionite as reducing agent. c. The observed pseudo-first order ET rate constant at 3 mM 
dithionite, the same concentration used in the enzyme activity assay using dithionite as 
reducing agent. d. Second-order rate constants of the reaction between IspH and 
dithionite. e. The cluster degradation rate constant of IspH+3 in air at 23°C. 
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Table 3.2 EPR g-values for EcIspH, AaIspH wild-type proteins and mutants in the 
absence or presence of 4.  
Samples g1 g2 g3 giso Δg 
EcIspH 2.025 1.899 1.876 1.933 0.149 
Ec291 2.007 1.907 1.797 1.904 0.210 
EcF302A 2.007 1.904 1.798 1.903 0.209 
EcY198A 2.011 1.907 1.796 1.905 0.215 
EcIspH+4 2.090 2.006 1.993 2.030 0.097 
Ec291+4 2.093 2.005 1.992 2.030 0.101 
EcF302A+4 2.093 2.005 1.992 2.031 0.100 
EcY198A+4 2.095 2.013 2.000 2.036 0.095 
AaIspH 2.022 1.903 1.842 1.922 0.180 
AaF14A 2.023 1.904 1.856 1.927 0.167 
AaY98A 2.021 1.898 1.849 1.923 0.172 
AaIspH+4 2.097 2.014 1.997 2.036 0.100 
AaF14A+4 2.096 2.015 1.997 2.036 0.099 
AaY98A+4 2.098 2.013 1.996 2.036 0.101 
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Chapter IV 
Structure, function, and inhibition of 4Fe-4S protein, 
DHAD 
4.1 Notes and Acknowledgments 
Dr. Ke Wang synthesized the compounds for the inhibition study. Dr. Jikun Li cloned 
the E. coli DHAD gene and purified the first batch of protein. Shanon Bouge assisted me 
with some of the protein purification and inhibition experiments. 
This work was supported in part by the United States Public Health Service (National 
Institutes of Health Grant GM065307), by a Harriet A. Harlin Professorship (E.O.), and 
by the University of Illinois Foundation/Oldfield Research Fund. 
 
4.2 Introduction 
 Tuberculosis is one of the most severe infectious diseases worldwide, causing 2-3 
million death per year, 95% of which occurs in developing countries. It is highly 
contagious due to the air-spread nature, and thus has posed a major threat to public 
health.1 The causative agent for tuberculosis is Mycobacterium tuberculosis, a small 
bacillus-shape bacterium that grows only inside host cells in nature. One unique feature 
of M. tuberculosis is the high lipid content of its cell wall,2 which accounts for many of its 
clinical characteristics. In lungs, M. tuberculosis is taken up by the macrophages, as part 
of the innate immune response. However, the cell walls of M. tuberculosis contains 
virulence factors that block the acidification and maturation of phagosome, as well as the 
fusion of phagosome with lysosome.3 Consequently, M. tuberculosis evades macrophage-
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killing and can multiply inside macrophages.4 Current prevention and treatment of 
tuberculosis largely relies on the Bacillus-Calmette Guerin (BCG) vaccine,5 and the 
chemotherapeutics using a combination of multiple drugs: isoniazid, rifampicin, 
ethambutol and pyrazinamide.6 However, due to the dormant nature of M. tuberculosis 
cells and the rise of drug-resistance strains, these approaches are never completely 
effective.  These barriers call the need for novel anti-tuberculosis therapies and drugs. 
Recently, a number of in vivo and in vitro studies suggested that, in macrophage, M. 
tuberculosis is unable to take up branched-chain amino acids (BCAAs): leucine, 
isoleucine or valine, and auxotrophic strains that cannot synthesize leucine are not able 
to replicate in macrophage. These observations can lead to a novel strategy against 
tuberculosis in macrophage, by targeting the biosynthesis of BCAAs that is not present in 
human. Previous gene knock-out and knock-down studies have identified several 
essential relevant genes. An isopropylmalate isomerase (leuCD) knock-out strain was 
used in tuberculosis vaccines in which an immune response is regenerated initially, then 
the bacteria are killed by the innate immune system.7 Plus, M. tuberculosis transformed 
with a plasmid encoding anti-sense mRNA of Dihydroxy-acid dehydratase (dhad) had 
poor growth in vivo, but grew normally when the medium was supplemented with 
BCAAs.8 These studies provide a basis for us to develop DHAD/LeuCD inhibitors 
targeting M. tuberculosis. 
DHAD and LeuCD are both 4Fe-4S cluster-containing proteins that catalyze non-redox 
hydration/dehydration reactions, Figure 4.1A, B, in which the 4th unique iron acts as a 
Lewis acid. In this study, we have focused on DHAD since LeuCD is a more complicated 
protein with two subunits (in bacterial) and a catalytic reaction that is more difficult to 
monitor. The enzymatic reaction and running mechanism is shown in Figure 4.1C.9 
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Interestingly, since plants also uses DHAD and LeuCD to synthesize branched-chain 
amino acids, inhibiting these enzymes is of considerable interest to the agrochemical 
industry as well. For example, DuPont reported10 an investigation of dozens DHAD 
inhibitors that are active against spinach and E. coli DHAD, Figure 4.2A. In the current 
study, we thus synthesized a series of analogues, Figure 4.2B, investigated their inhibition 
against DHAD from E. coli as well as M. tuberculosis, and further evaluated their activity 
against different bacterial cells. 
 
4.3 Results and Discussion 
4.3.1 DHAD/LeuCD/aconitase belong to the same protein family. 
DHAD and LeuCD both catalyze dehydration reactions, similar to aconitase. Using a 
sequence similarity analysis,11 we generated a network view, Figure 4.3, showing the 
DHAD family proteins including DHAD, LeuCD, aconitase (both type 1 and type 2), as 
well as 6-phosphogluconate dehydratase, suggesting a similar fold for these proteins. The 
X-ray structure of 6-phosphogluconate dehydratase from Shewanella oneidensis (PDB 
code: 2GP4) is known, although only in its apo-form without the Fe-S cluster bound. 
Using Phyre2,12 the structure of DHAD and LeuCD were well modeled (~100% confidence) 
from 6-phosphogluconate dehydratase, Figure 4.4. The model structure of DHAD (and 
other proteins in the family) has 2 domains: a larger domain containing the conserved 3 
cysteines to harbor the 4Fe-4S cluster, and a smaller domain containing residues for 
substrate binding. Notably, there are two types of LeuCD. In prokaryotes, there are two 
genes encoding for LeuC and LeuD, respectively, and they form a protein complex to 
function properly. While in eukaryotes such as Aspergillus fumigatus and Candida 
albicans, there is now only a single protein containing both LeuC and LeuD domains. The 
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structure of LeuD from the M. tuberculosis has been reported,13 and more recently, the 
structure of the large catalytic domain of LeuC from Methanococcus jannaschii was also 
reported,14 albeit minus the 4Fe-4S cluster since the protein was purified aerobically. No 
DHAD structure is reported, and we are currently working with Professor Michael Groll 
to determine its X-ray structure.  
4.3.2 Enzymatic assays of EcDHAD and MtDHAD. 
Both EcDHAD and MtDHAD can be readily cloned and expressed in recombinant E. 
coli. The Isc system was used in both cases to help the incorporation of Fe4S4 cluster, and 
both proteins can be purified with a dark brown color. E. coli DHAD encodes a 
polypeptide of 615 residues, while MtDHAD contains 575 residues; both proteins are 
purified with correct size. 
DHAD catalyzed the dehydration of 2, 3-dihydroxy-3-methlbutanoate, yielding a α-
keto carboxylate, which has weak UV absorbance. In order to monitor the reaction, an 
end point assay was used in which the product was converted to hydrazone by sequential 
treatment of 2, 4-dinitrophenylhydrazine and strong base, Figure 4.5. The final product 
has strong absorption at 570 nm which can be used to quantify the reaction. Based on 
their work, I developed a 96-well plate-based assay which can be performed in a high-
throughput manner (see Materials and Methods for details) for inhibitor screening. 
DHAD is a [Fe4S4]2+ cluster- containing protein. The cluster can usually be reduced to 
[Fe4S4]+, by using dithionite or other electron donors. Interestingly, reduced DHAD is 
also active, although the activity is lower, 66% of the oxidized ([Fe4S4]2+) enzyme. A 
possible explanation is that reduced +1 Fe-S cluster has less positive charges, and 
becomes a weaker Lewis acid compared to the +2 cluster.  
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4.3.3 Inhibition of EcDHAD and MtDHAD. 
In their research for new herbicides, Flint and Nudelman at DuPont developed a series 
of DHAD inhibitors that have activity against spinach DHAD. They also reported that 
these inhibitors had similar activity against E. coli DHAD. Shown in Figure 4.2A is a small 
selection of the inhibitors developed, together with their Ki’s. Apparently, these inhibitors 
are substrate analogues that competitively inhibit the enzyme. These results provided a 
good starting point for our work. In the current work, we synthesized 34 analogues of 
these compounds, Table 4.1 and Figure 4.2B, and tested their inhibition against both 
EcDHAD and MtDHAD. The results are summarized in Table 4.1, and discussed below in 
different categories of compounds. 
(i) 2, 3-dihydroxy carboxylic acids. In the original paper of Flint and Nudelman,10 the 
best inhibitor they obtained is 2, 3-dihydroxy-octanoic acid, with a Ki value of 300 nM, 
Figure 4.2A. In our study, however, this compound is not inhibiting the catalysis, as 
indicated by NMR analysis. In any cases, we synthesized a series of dihydroxy-acid 
analogues with aliphatic and aromatic tails. We observed, though, considerable inhibition 
for DHAD with analogues containing longer aliphatic chain. The best inhibition activity 
was obtained with compound 1580A, with an IC50 of ~7 μM for EcDHAD and ~28 μM 
for MtDHAD, Table 4.1, corresponding to Ki values of 2 μM and 9 μM respectively. A 
series of analogues with different chain lengths, C7-C18, were investigated. The best 
inhibition occurs at C14, as abovementioned, and compounds with longer or shorter 
carbon chains have worse inhibition. For example, compound 1581A, C15, has IC50 of 38 
µM, compound 1608A, C13, 13 µM, and compound 1579A, C12, 22 µM, Table 1. These 
compounds all have much longer fatty chain compared to the substrate, indicating the 
presence of a long hydrophobic pocket. All analogues containing aromatic groups directly 
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linked to the dihydroxy moiety didn’t show any inhibition, probably due to the size and 
rigidity of the phenyl ring(s). However, compound 1617A that harbors a phenyl ring at 
the terminus of the aliphatic chain showed good activity, 12 µM, similar to that of the C12 
compound, 1608A, indicating that the binding pocket favors more flexible aliphatic 
chains.   
(ii) 2-hydroxyphosphonic acids. Another class of previously reported compounds 
contain the 2-hydroxyphosphonic acid moiety linked to aromatic groups, with IC50 of 20 
µM, Figure 4.2A. We also synthesized a series of 2-hydroxyphosphonic acids with 
different aromatic and aliphatic tails. However, none of these compounds showed any 
activities in our assay, probably due to the presence of the bulky aromatic groups. 
(iii) 3-hydroxyphosphonic acids. This class of compounds were not reported previously, 
but due to their structural similarity to the above two classes, we synthesized two 
analogues with different aliphatic chains linked to the 3-hydroxyphosphonic acid moiety, 
1607A and 1613A. Both compounds showed some activity, with IC50s 130 µM and 150 
µM respectively, Table 4.1. In general, phosphonic acids exhibited much less activities 
comparing to carboxylic acids, probably due to the larger size of the phosphonic groups, 
or that the presence of two adjacent hydroxyl groups is crucial to the activity. 
4.3.4 Cell activities of some inhibitors. 
From the inhibition studies, we obtained several good lead for DHAD inhibition, we 
next then investigated whether these compounds are active in cell growth inhibition 
assays. We first screened these compounds against different bacteria: E. coli, Bacillus 
subtillis, and Mycobacterium smegmatis, and the results are summarized in Table 1. In 
general, most compounds did not show significant inhibition. Several compound are of 
interest and will be discussed below. 
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In E. coli, the assays were performed in rich medium, in which DHAD inhibition would 
not be essential for cell growth. Indeed, not much activities were observed for the 
compounds tested, except compound 1589A and 1590A which exhibited some inhibition 
activity with IC50s of 82 and 114 µM respectively. The fact that these compounds actually 
inhibit the growth of E. coli indicated that they might have other targets in the cells, and 
in fact, some of these compounds have good activities against undecaprenyl diphosphate 
synthase (UPPS), as indicated by another study from our group. 
In B. subtilis, the growth assays were performed in a synthetic medium consisted of 
amino acids and inorganic salts. In such medium, several compounds showed good 
activities. The most potent compounds are 1580A and 1581A which exhibits best activity 
in the enzymatic assays, with a cell inhibition IC50 of 4 µM for both compounds. 
Interestingly, these two compounds did not inhibit the growth of B. subtilis in rich 
medium such as LB. It is thus possible that LB medium contains certain growth factor 
whose biosynthesis was inhibited in the case of synthetic medium. Several of vitamins, 
thiamine, biotin, pyridoxine and VB12 were added to the synthetic medium but no 
significant rescue was observed, indicating that other compounds are responsible for this 
observation. Interestingly, compound 1607A showed a bit activity, IC50 of 175 uM, when 
the medium does not contain any branched-chain amino acids, and this inhibition can be 
rescued when ILV was supplemented into the medium, suggesting that this compound 
might target DHAD inside cells as we proposed. 
In the case of M. smegmatis, the assays were performed in a synthetic 7H9 medium. 
None of the compounds showed significant cell growth inhibition. Only compounds 
1589A, 1590A and 1607A has IC50s of 61, 72 and 140 µM respectively. 
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4.4 Conclusion 
In conclusion, we cloned and expressed active DHAD from E coli and M tuberculosis. 
A library of 34 compounds were synthesized and their activities were investigated against 
DHAD. Several inhibitors have IC50s at a few micromolar. These compounds were also 
tested against various bacteria and some of them showed good activities against B. subtilis 
in a synthetic medium. Overall, the results are of interest since they provide some 
preliminary data for this novel anti-tuberculosis strategy.   
 
4.5 Materials and Methods 
4.5.1 Expression and purification of DHAD. 
E. coli dhad gene (also known as ilvD) was amplified from the genomic DNA of E. coli 
K-12 strain and cloned into pET-28a (+) vector. Sequence verified plasmid was 
transformed into E. coli BL21 (DE3) competent cells (Agilent, CA) together with a plasmid 
encoding the Isc system that catalyzes the formation of the 4Fe-4S cluster. For protein 
expression, one liters of recombinant E. coli culture was inoculated with 5 ml of overnight 
culture and grown at 37 °C. Cells were induced first at OD600 of 0.6 with 100 mg/L cysteine, 
0.1 mM ferric citrate and 2 g/L arabinose for the expression of Isc system, and then at 
OD600 of 0.8 with 1 mM isopropyl β-D-1-thiogalactolpyranoside (IPTG). The expression 
was continued at 22 °C for 24 hrs. The cells were then harvested by centrifugation and 
stored at -80 °C for further usage. All protein purification steps were performed in an 
anaerobic chamber (Coy Lab, IL) with O2 level <1 ppm. Briefly, cell pellets were thawed 
and suspended in ~20 ml loading buffer (50 mM Tris/HCl, 150 mM NaCl, 10 mM 
imidazole, pH=8.0) containing 2 mg/ml lysozyme, 10 μL benzonase and protease 
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inhibitors. Cell suspension was then lysed by sonication and centrifuged to remove the 
debris. The clear lysate was loaded into a gravity column containing Ni-NTA resin. The 
resin was washed with washing buffer (50 mM Tris/HCl, 150 mM NaCl, 50 mM imidazole, 
pH=8.0), and the protein was eluted with elution buffer (50 mM Tris/HCl, 150 mM NaCl, 
250 mM imidazole, pH=8.0). The brown faction was collected, desalted with a PD-10 
column to remove the imidazole and concentrated to desired concentration. 
For M. tuberculosis DHAD, Mtdhad gene (also known as Rv0189) was amplified from 
the genomic DNA of M. tuberculosis H37Rv strain [ATCC® 27294TM]. All other 
procedures were the same to EcDHAD. 
4.5.2 DHAD activity and inhibition assay. 
Activity assays were performed in an anaerobic chamber with O2 level <1 ppm. The 
catalytic activity of DHAD was assayed using a modified protocol from previous report9 
that it can be performed in a high-throughput manner. For activity assays, 90 μL working 
solution (50 mM Tris/HCl, 150 mM NaCl, pH=8.0) containing 100 nM E. coli DHAD or 
150 nM M. tuberculosis DHAD, 1 mM (±)-2, 3-dihydroxy-3-methylbutanoate and 5 mM 
Mg2+ was incubated in a 96-well plate at 37 °C for 30 min. The reaction was stopped and 
the product derivatized by adding 30 μL 2 mM 2, 4-dinitrophenylhydrazine in 4 M HCl 
and incubated for additional 20 min at room temperature (25 °C). Finally, 90 μL of 5 M 
NaOH was added to the wells and incubated for 10 min before reading the absorbance at 
550 nm. For inhibition assays, 200 μM compound was added to the 96-well plate, and 
this solution was 3x-serial diluted, by using the working solution, into a final 
concentration of 91 nM (1/2187 of original concentration). The enzyme was incubated 
with inhibitors for ~20 min before the reaction. Fraction activities at various inhibitor 
concentrations were plotted with a dose-response curve in Origin. 
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4.5.3 Synthesis of inhibitors. 
The inhibitors used in this study was synthesize by Dr. Ke Wang, and the synthetic 
procedure is reported in an unpublished work from our group.  
4.5.4 Bacterial strains and medium. 
Mycobacterium smegmatis ATCC 700084, Bacillus subtilis subsp. subtilis ATCC 6051 
and E. coli ATCC 29425 were from American Type Culture Collection (ATCC). For cell 
growth experiments, E. coli cells were grown in LB medium; B. subtilis cells were grown 
in a synthetic media with the following composition: 20 mM valine, 2.4 mM arginine, 7.0 
mM leucine, 4.2 mM threonine, 6.0 mM serine, 25 mM glutamic acid, 14 mM alanine, 10 
mM asparagine, 25 mM glucose, 0.4 mM MgCl2, 10 mM KH2PO4, 0.75 mM Na2SO4, 0.1 
mM CaCl2, 0.0036 mM FeCl2, 10 mM NH4Cl, 0.1 mM MnCl2, 1.2 mM NH4NO3, valine and 
leucine are omitted when –ILV medium was used; and M. smegmatis cells were grown in 
the 7H9 medium supplemented with 10% ADC enrichment. 
4.5.5 Cell growth inhibition assay. 
E. coli cell growth inhibition was assayed with a MTT ((3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide)-based assay. E. coli K-12 culture was grown to mid-log 
phase with an OD600 of 0.4. The culture was then diluted by 500 fold into fresh LB 
medium. 100 μL of this working culture was inoculated into a 96-well plate containing 
500 μM inhibitor, and this solution was 2X-serial diluted into a final of 488 nM (1/1024 
of original concentration). The plate was incubated for 3 h at 37 °C to mid-log phase. 10 
μL of MTT reagent was then added to the bacteria culture, followed by incubation for 3 h 
or until the purple color had developed. 100 μL of detergent solution was then added to 
the culture and incubated in dark for 1 h at 22 °C before reading the absorbance at 570 
nm. Does-response curves were fitted with Origin. 
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Bacillus subtilis and Mycobacterium smegmatis cell inhibition assays were both 
performed by an OD600-based method. Briefly, mid-log phase (OD600~0.4) of bacterial 
culture was diluted to OD600 of 0.01 as working solution. This working solution was 
inoculated into a 96-well plate containing 500 μM inhibitor, and this solution was 2X-
serial diluted into a final of 488 nM (1/1024 of original concentration). The plate was 
incubated at 37 °C for 12 h (B. subtilis) or 24h (M. smegmatis) before reading the OD600. 
Dose-response curves were fitted with Origin.  
 
4.6 Figures and Tables 
 
 
Figure 4.1 (A) Reaction catalyzed by DHAD. (B) Reaction catalyzed by LeuCD. (C) 
Running mechanism for DHAD catalysis. The cube indicates the Fe4S4 cluster. 
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Figure 4.2 (A) DHAD inhibitors synthesized by Flint et. al. (B) The three classes of 
compounds synthesized in this study.  
 
 
 
Figure 4.3 Sequence similarity network view of DHAD family proteins. Green: bacteria; 
red: eukaryote; blue: archaea. 
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Figure 4.4 Phyre2 models of DHAD and LeuCD, compared to aconitase. 
 
 
 
Figure 4.5 Assay for DHAD reaction. 
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Table 4.1 IC50 values of the compounds in this study against different enzymes and cells. 
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Table 4.1 (cont.) 
 
110 
 
Table 4.1 (cont.) 
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Chapter V 
SQ109 analogues as multi-target anti-tuberculosis and 
anti- trypanosomiasis drug leads 
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5.2 Introduction 
As mentioned in Chapter 1, there is a need for novel drugs due to the appearance of 
drug-resistant pathogens, and these new drugs are more attractive if they can be more 
“resistance-resistant”. One possible approach is to targeting virulence factors instead of 
essential genes, which can generate less survival stress on the pathogens, and reduce the 
chance of resistance.1 Another approach is to target less mutable molecules other than 
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proteins, with Texobactin as a recent example.2 Texobactin binds to the lipid precursors 
involved in cell wall biosynthesis, and resistance was not developed. A third approach is 
combinatory therapy that uses different drugs for different targets;3 however, the cost for 
developing such therapy would be multiplied as well. A fourth approach is to use “multi-
targeting” strategy in which a single drug has more than one target.4 While one drug has 
multiple targets may sound challenging, it is actually not uncommon for many drugs.  
As mentioned in Chapter IV, there is a need for new TB drugs due to the rapidly-
appearing multidrug resistant strains. In this study, we investigated the mode of action of 
SQ109 (Figure 5.1), a novel tuberculosis (TB) drug lead currently in Phase II clinical trials. 
SQ109 is developed in a screening program against ~64000 ethambutol analogues.5 
SQ109 has been proved to be very active against M. tuberculosis, with a minimal 
inhibition concentration (MIC) of ~1 µM against drug-resistant strains, and many other 
bacteria (E. coli, B. subtilis, S. aureus, M. smegmatis), fungal (S. cerevisiae, Candida 
albicans) and protozoa (P. falciparum).6 More interestingly, resistance has not been 
developed upon adaptive evolution against SQ109, suggesting a complicated mode of 
action. We sought to identify possible target(s) of SQ109 along with its bioactive 
analogues. 
 
5.3 Results and Discussion 
5.3.1 SQ109 analogues target broad range of organisms. 
To investigate the essential structural component for SQ109, we synthesized a series 
of analogues of SQ109 (Figure 5.1) in which the ethylenediamine linker was replaced with 
different groups, as well as analogues with the adamantyl head group varied. As shown in 
Table 5.1, many of these analogues are active against a broad range of bacteria, fungi, and 
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protozoa cells. Interestingly, compounds 2 and 12 have improved activities against M. 
tuberculosis compared to SQ109, indicating that only one cationic nitrogen center is 
required for the activity. The improved activities were also seen in Staphylococcus aureus, 
where SQ109 itself is almost inactive while several analogues with one nitrogen in the 
linker region showed moderate activities. In all the different species tested, the activities 
of SQ109 analogues has moderate to good correlations, suggesting a possible common 
mode of action. The fact that SQ109 analogues are active among various species also 
suggests a different target of SQ109 than the previous assumed membrane transporter, 
MmpL3, since this target is absent in most other organisms. We next sought to explore 
what additional targets might be for these compounds. 
5.3.2 Possible protein targets of SQ109 analogues. 
SQ109 contains a C10 isoprenoid side chain and a basic ethylenediamine moiety which 
is a cationic center at physiological condition. SAR study using SQ109 analogues revealed 
that at least one cationic center, specifically a protonatable nitrogen is required for its 
potency. These structural features suggest a possible prenyltransferase inhibitor that can 
mimic the carbocation transition state in the isoprenoid biosynthesis. It was thus first 
tested against a series of “head-to-tail” prenyltransferase. However, no significant 
inhibition was observed in all cases except human GGPPS (IC50=4.5uM). It is not 
surprising since SQ109 also contains a rigid and hydrophobic adamantanyl group which 
is not required in the inhibition of these “head-to-tail” prenyltransferases.7 Instead, this 
features could be present in the transition state of “head-to-head” prenyltransferase, as 
well as the enzymes involved in quinone biosynthesis. However, known and putative 
head-to-head prenyltransferases in those bacteria either have varied product or are not 
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vital for survival, suggesting different targets, which is also confirmed by the weak 
inhibition results against CrtM and SQS.  
Another possible candidate are the enzymes involved in quinone biosynthesis or 
quinone utilization. One of the most obvious enzyme of interest is the prenyltransferase 
MenA, which catalyzes the isoprenylation of 1, 4-dihydroxy-2-naphthoate with polyprenyl 
pyrophosphates8, Figure 5.2A, and is also of interest as a drug target.9 The possible 
reaction intermediate adopts a naphthalene ring-cabocation-isoprene side chain 
configuration, similar to SQ109 analogues. Initial inhibition assays using M. smegmatis 
MenA containing membrane fractions revealed an IC50~6µM.9  
Encouraged by this results, we tried to overexpress MenA for a more direct 
examination. There have been some difficulties expressing M. tuberculosis MenA 
(MtMenA) due to its extremely low yield as a trans-membrane protein. Initial trials using 
fusion partners such as thioredoxin and MBP or co-expression with helper proteins (ATP 
synthase β-subunit for example) didn’t help, neither did the N or C terminus truncation 
mutants, assuming that MenA could possibly be a monotopic protein that has only one 
TM helice on the terminus. Fortunately, the E. coli MenA (EcMenA) could be expressed, 
although with a yield as low as ~0.1 mg/L cell culture. A detergent based HPLC and all 
the SQ109 analogues were examined against EcMenA, Figure 5.2B. Interestingly, the best 
inhibitor against EcMenA was also the most potent against M. tuberculosis cell growth 
(and E. coli cell growth, within error). There was also a moderate correlation between 
EcMenA inhibition and E. coli cell growth inhibition, with a R2=0.46 using both pIC50 
values, Figure 5.2C, suggesting MenA inhibition could be involved in cell growth 
inhibition, but other targets could also be involved. 
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The structure of MenA is unknown. However, it is predicted to be a transmembrane 
protein with 9 α-helices, Figure 5.3A.10 Using second structure based prediction program, 
Phyre2,11  MtMenA was modeled to have almost the same fold as Aeropyrum pernix 
hydroxybenzonate octaprenyltransferase (UbiA, PDB ID 4OD5), with >90% accuracy. 
The two Asp rich sites (DDXXD and DXXXD) that are essential for Mg2+ binding and 
catalysis in prenyltransferase are shown in Figure 5.3B. UbiA catalyzes the isoprenylation 
of 4-hydroxybenzonate, a reaction similar to that catalyzed by MenA. Therefore, the 
binding sites of the substrates for UbiA, GPP and 4-hydroxybenonate (Figure 5.3C), 
would be close to that in MenA. Moreover, the Asp rich sites are also located close to the 
same sites in CrtM, based on a CrtM-SQ109 X-Ray structure, Figure 5.3D.12 This 
alignment can provide the possible binding sites of SQ109 in MenA. The two Asp-rich 
sites are also highly conserved in MenA according to the SCORECONS analysis.13 These 
bioinformatics predictions also agree our hypothesis and observation that the cationic 
SQ109 analogues inhibit MenA by mimicking the reaction intermediate, and thus 
inhibiting quinone biosynthesis. In fact, the SQ109 inhibition can be rescued by 
menaquinone-4 in M. tuberculosis, in accordance with its role as quinone biosynthesis 
inhibitor. 
5.3.3 SQ109 can also collapse Proton Motive Force (PMF). 
According to more extensive studies with our collaborators, we found that SQ109 
analogues have activity against many other cell events, including cell respiration/electron 
transport, consequently ATP synthesis, and proton motive force (PMF) across the 
membrane. While the inhibition on respiration and electron transport could be partially 
attributed to the inhibition of quinone biosynthesis, SQ109 also have a direct effect on 
PMF, acting as uncoupler, collapsing pH gradient and membrane potential. As shown in 
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Figure 5.4, in an E. coli inverted membrane vesicle (IMV) system, SQ109 and other active 
analogues induced a rapid collapse in ΔpH, while other inactive analogues had no effect. 
Taken this into consideration, the E. coli cell growth inhibition can be better modeled 
using MenA inhibition and PMF collapse as two descriptors, with a R2=0.77, comparing 
to the abovementioned value of 0.46 using MenA inhibiton solely (Figure 5.2D). Together 
with the previous studies that SQ109 could inhibit the transportation of trehalose 
monomycolate,14 a necessary building block in M. tuberculosis cell wall, it is possible to 
propose the modes of action of SQ109 analogues as multi-target inhibition in 
mycobacterium, Figure 5.5, providing a potent resistant-resistance therapy for TB and 
other infectious diseases. 
5.3.4 SQ109 analogues as Trypanosoma brucei drug leads. 
In a followed-up study,15 a total of 42 more SQ109 analogues with various head groups, 
cationic centers and aliphatic chains, were synthesized and tested against different cells. 
These inhibition results for selected compounds are summarized in Table 2. While not 
much improvement was seen against M. tuberculosis, it is of particular interest that some 
of the compounds have good activity against Trypanosoma brucei, the causative agent 
for human African trypanosomiasis or “sleeping sickness”,16 a life-threatening tropical 
disease without effective and reliable therapies. The best two SQ109 analogues had IC50 
values in the 5-7 ng/ml range with a therapeutic index of ~300. 
 
5.4 Conclusion 
In summary, our study is of interest for several reasons. First, it was shown that 
tuberculosis drug SQ109 and its analogues are potent drug leads for various bacteria, 
fungi and protozoa species. Second, the mode of action of SQ109 family compounds are 
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“multi-targeting” that they can both inhibit prenyltransferase activity and collapse the 
proton motive force across the membrane. Third, such a network inhibition mechanism 
raises the possibility of developing more potent compounds that are “resistance-resistant”, 
due to “multi-targeting”. 
 
5.5 Methods and Materials 
5.5.1 Expression and purification of EcMenA.  
The gene encoding EcMenA with an N-terminal strep tag was amplified by polymerase 
chain reaction (PCR) with forward primer 5′-GACGACGACAAGATGAGCGCGTGGAGCC 
ATCCGCAGTTTGAAAAAGGCGGTGGCAGCGCGGAGAATCTTTATTTTCAGGGCGCTGG
TGC-3′ and reverse primer 5′-GAGGAGAAGCCCGGTTATTATGCTGCCCACTGGCTTAG 
GAATAT-3′, and then cloned into the pET46 Ek/LIC vector. The recombinant plasmid 
was transformed to E. coli C43 (DE3) and the protein induced with 1 mM isopropyl 
thiogalactopyranoside (IPTG) at 37 °C for 5 h. The cell paste was harvested by 
centrifugation at 7000g and resuspended in buffer A containing 25 mM Tris-HCl, pH 7.5, 
150 mM NaCl, and 20 mM imidazole. A cell lysate was prepared with a JNBIO pressure 
cell (JN-3000 PLUS), the membrane, and soluble proteins being separated by 
ultracentrifugation at 150000 g for 1.5 h. The resulting pellet was solubilized by 
incubation in buffer A supplemented with 1% (w/v) DDM detergent overnight at 4 °C. The 
latter solution was centrifuged (100 000g for 1 h at 4 °C in a Beckman Ti70 rotor) and the 
supernatant loaded onto a Ni-NTA column and washed with buffer A containing 0.05% 
DDM. The buffer and gradient for the Ni-NTA column were 25 mM Tris, pH 7.5, 150 mM 
NaCl, 0.05% DDM, and 20−500 mM imidazole. The protein was then loaded onto a Strep-
Tactin (IBA) column equilibrated with washing buffer containing 100 mM Tris-HCl, pH 
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8.0, 150 mM NaCl, 1 mM EDTA, and 0.05% DDM and washed with five column volumes 
of washing buffer. EcMenA was finally eluted with eluting buffer containing 100 mM Tris-
HCl, pH 8.0, 150 mM NaCl, 1 mM EDTA, 0.05% DDM, and 2.5 mM desthiobiotin. The 
purified protein was finally concentrated to 5 mg mL−1 in a 25 mM Tris-HCl, pH 7.5, 150 
mM NaCl, 0.05% DDM buffer. 
5.5.2 EcMenA inhibition assay. 
Inhibition of EcMenA was carried out using an HPLC-based protocol. Typically, 2.5 
μg of EcMenA in 100 μL of reaction buffer (25 mM Tris-HCl, 0.1% Triton X-100, 250 μM 
MgCl2, 10 mM DTT, pH = 7.5) was incubated with inhibitors for 30 min at 22 °C. 1,4-
Dihydroxy-2-naphthoic acid (DHNA) and farnesyl diphosphate (FPP) were then added to 
the enzyme solution to a final concentration of 150 μM each. The reaction was incubated 
at 37 °C for 3 h before quenching with 50 μL of 0.1 M acetic acid in methanol containing 
50 μM menaquinone-4 (MK-4, Sigma-Aldrich) as an internal standard. The mixture was 
then extracted with 600 μL of hexane by vortexing. After centrifugation, 500 μL of organic 
layer was collected and dried under nitrogen then dissolved in 200 μL of methanol. 
Twenty microliters of the methanol solution were then subjected to HPLC analysis (0.1% 
formic acid in H2O to 0.1% formic acid in CH3CN, UV: 325 nm, 250 μL/min). The amount 
of the MenA reaction product demethylmenaquinone-3 (DMMK-3) was determined by 
comparison of integrated peak areas between DMMK and the internal standard MK-4. 
IC50 values were estimated by using Origin 6.1 software to analyze the dose−response 
curves. 
5.5.3 Bacterial strains and medium. 
Mycobacterium smegmatis ATCC 700084, Bacillus subtilis subsp. subtilis ATCC 6051 
and E. coli ATCC 29425 were from American Type Culture Collection (ATCC). For cell 
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growth experiments, E. coli cells were grown in LB medium; B. subtilis cells were grown 
in a synthetic media with the following composition: xxx; and M. smegmatis cells were 
grown in the 7H9 medium supplemented with 10% ADC enrichment. 
5.5.4 Cell growth inhibition assay. 
E. coli cell growth inhibition was assayed with a MTT ((3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide)-based assay. E. coli K-12 culture was grown to mid-log 
phase with an OD600 of 0.4. The culture was then diluted by 500 fold into fresh LB 
medium. 100 μL of this working culture was inoculated into a 96-well plate containing 
500 μM inhibitor, and this solution was 2X-serial diluted into a final of 488 nM (1/1024 
of original concentration). The plate was incubated for 3 h at 37 °C to mid-log phase. 10 
μL of MTT reagent was then added to the bacteria culture, followed by incubation for 3 h 
or until the purple color had developed. 100 μL of detergent solution was then added to 
the culture and incubated in dark for 1 h at 22 °C before reading the absorbance at 570 
nm. Does-response curves were fitted with Origin. 
B. subtilis growth inhibition were determined by using a microbroth dilution method. 
A stationary starter culture of B. subtilis was diluted 50-fold into fresh LB broth and 
grown to an OD600 of ∼0.4. The culture was then diluted 500-fold into fresh LB medium 
to give a working solution, and then 100 μL of working solution was transferred to each 
well of a 96-well flat-bottom culture plate (Corning Inc., Corning, NY). Inhibitors were 
then added at 0.5 mM and 2× serial diluted to 500 nM, the volume and solvent 
composition constant. Plates were incubated for 12−16 h at 37 °C, and the absorbance at 
600 nm was determined. A nonlinear regression analysis was carried out using Origin 6.1 
to obtain the IC50 values. 
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S. cerevisiae growth inhibition assay was the same as for B. subtilis except that YPD 
instead of LB was used as the culture medium, and the 96-well plates were incubated for 
48 h instead of 12−16 h. 
Mycobacterium smegmatis cell inhibition assay was also the same as for B. subtilis 
except that 7H9 medium (with 10% ADC enrichment) was used as the culture medium, 
and the 96-well plates were incubated for 36 h. 
 
5.6 Figures and Tables 
 
 
Figure 5.1 SQ109 and its analogues. 
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Figure 5.2 (A) The reaction that MenA catalyzes in menaquinone biosynthesis. n=3 in 
in vitro assay; 8, 9 in M. tuberculosis cells. MenA product was auto-oxidized into quinone 
in air but the quinol form is the substrate for the following reactions. (B) Inhibition data 
of EcMenA, growth of E. coli and M. tuberculosis by SQ109 analogues. a: IC50, µM; b: IC50 
µg/mL; c: MIC90, µg/mL. (C) Correlation between E. coli cell growth inhibition and 
EcMenA inhibition. (D) Modelling of E. coli cell growth inhibition using EcMenA 
inhibition and proton motive force (PMF) collapse as descriptors. 
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Figure 5.3 (A) Transmembrane prediction of MtMenA. (B) Phyre2 prediction of 
MtMenA with conserved Asp rich sites in magenta. (C) Alignment of MtMenA model 
(cyan) and Aeropyrum pernix UbiA (gold). The two substrates for UbiA, 
geranylpyrophosphate and 4-hydroxybenzonate are shown in purple and green, 
respectively. (D) Alignment of MtMenA model (cyan) and S. aureus CrtM (pink)+SQ109 
(red). Asp rich sites in CrtM are shown in orange. 
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Figure 5.4 The effect of SQ109 analogues on proton motive force cross the membrane. 
(A) ΔpH collapse in E. coli IMVs by a known uncoupler SF6847. (B) ΔpH collapse in E. 
coli IMVs by 1 and 4. (C) Effects of 1 and analogues on Δψ in M. smegmatis cells. (D) 
Effects of 3 on ATP biosynthesis of effect in M. smegmatis cells. 
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Figure 5.5 Proposed modes of action of SQ109. MenA and MenH inhibitions affect 
respiration. PMF (∆pH, ∆ψ) collapse leads to decreased ATP biosynthesis, and 
subsequently ATP/PMF powered cross-membrane transportation. MmpL3 and MmpL11 
inhibitions limit import of heme and mycolic acid-containing lipids. TMM: trehalose 
monomycolate. 
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Table 5.1 Inhibition by 1 and analogues of M. tuberculosis (Mt), M. smegmatis (Ms), S. 
aureus (Sa), B. subtilis (Bs), E. coli (Ec), S. cerevisiae (Sc), C. albicans (Ca), P. falciparum 
(Pf), and Human (MCF-7) Cell Growth (in µg/mL). 
 Mt Ms Sa Bs Ec Sc Ca Pf MCF-7 
1 0.1-0.2 3.1 >120 7.6 2.8 1.1 3.3 1.0 6.0 
2 0.02-0.05 1.6 8 16 2.8 1.8 12 0.79 10 
3 0.19 6.2 >120 66 4.3 33 >66 0.93 112 
4 50 >50 >64 66 >332 >332 >66 7.9 73 
5 1.6 6.2 8 3.0 2.3 2.7 6.5 0.83 3.4 
6 0.78 12 8 4.2 37 15 18 0.08 3.2 
7 0.78 6.2 >120 69 >345 >69 >69 6.2 12 
8 12 25 >120 17 >1345 >69 >69 3.8 9.3 
9 6.2 50 16 50 126 44 50 3.2 45 
10 6.2 12 32 17 60 3.0 20 14 6.3 
11 6.2 12 8 2.4 15 3.7 12 100 7.1 
12 0.05 1.6 8 1.8 12 0.89 6.3 2.0 1.3 
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Table 5.2 Growth inhibition of various cells by selected SQ109 analogues that are 
active against T. brucei.  
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Chapter VI 
Biochemical and spectroscopic investigation of lysyl 
oxidase 
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6.2 Introduction 
Human lysyl oxidase (LOX, EC 1.4.3.13) is a copper protein that oxidize lysine residues 
presumably to the corresponding aldehyde in primarily collagens and elastin, the 
aldehyde then crosslinking with the lysine 6-amino groups, ultimately resulting in non-
enzymatic formation of the cross-links responsible for the mechanical strength and 
flexibility of these important structural proteins.1 LOX expression is regulated by hypoxia-
inducible factors (HIFs) and is highly upregulated in many breast and lung tumors.2 This 
has been proposed to result in increased collagen IV cross-linking, essential for CD11b+ 
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myeloid cell recruitment and MMP2 formation—which then cleaves collagen—providing 
the “pre-metastatic niche” for recruitment and invasion of circulating tumor cells. More 
recently, Cox et al.3 have shown that LOX released by tumor cells under hypoxia also has 
a major effect on osteoclastogenesis and bone remodeling: LOX activates pre-osteoclasts 
that differentiate into active osteoclasts, and inhibits osteoblasts, Figure 6.1. The result is 
the break-down of bone homeostasis with significant bone destruction, and the formation 
of the pre-metastatic niche. Compounds such as β-aminopropionitrile and 
tetrathiomolybdate (MoS42-) are LOX inhibitors and have been found to inhibit 
metastases in mice models,4 as does LOX inhibition with a LOX antibody.5 This discovery, 
combined with our previous studies on bone-targeting bisphosphonates, thus opened up 
the possibility of developing bisphosphonates LOX inhibitors as bone-targeting cancer 
therapeutics. 
Given its important roles in collagen and elastin crosslinking and hence angiogenesis, 
LOX is one of the most interesting amine oxidase. However, it is also the least 
characterized and most difficult one to treat experimentally, due to its low solubility in 
the absence of urea and low activity in the enzymatic assays.  LOX catalyzes the oxidation 
of lysine with a unique quinonoid factor called LTQ, the lysine-tyrosine-quinone cofactor, 
plus a mononuclear copper center. Proposed catalytic cycles for the formation of LTQ 
cofactor, as well as the lysine side-chain oxidation, are shown in Figure 6.2. The role of 
the copper center is to oxidize the aminophenol intermediates during LTQ biogenesis, 
and normal catalysis. To date, there is no X-ray or NMR structure reported for LOX. 
Biochemical studies on this enzyme are also few. It is thus of great interest to investigate 
the structure of LOX as a prelude to developing new inhibitors. 
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In this study, we aimed to investigate which residues are essential for catalysis and 
copper binding. We have used biochemical and spectroscopic characterizations to give 
preliminary results on the active sites of this protein.  
 
6.3 Results and Discussion 
6.3.1 The LOX family proteins. 
There are actually several LOX proteins in human: LOX and LOX-like protein (LOXL1 
to LOXL4), Figure 6.3A. These proteins all contain a conserved C-terminal catalytic 
domain that harbors the quinonoid cofactor as well we the copper center. Their N-
terminals, however, are quite different, being either a proline-rich N-terminal domain 
(LOXL1) or a series of scavenger-receptor cysteine-rich domains (LOXL2, 3 and 4).1d The 
LTQ-containing LOXs are also present in other multicellular eukaryotes, some bacteria 
(mainly myxobacteria and actinomyces), as well as a single case in fungi. Notably, there 
is a different class of LOX, the trihydroxyphenylalanine quinone (TPQ) cofactor-
containing LOX whose X-ray structure is known (PDB ID 1W7C6). These two classes of 
LOXs have different cofactors and no sequence similarity. 
Since there is no structural information of LOX, and structural model programs failed 
to provide any meaningful results, we first analyzed the conserved residues in LOX and 
LOXL proteins with SCORECONS,7 Figure 6.3B. First, as expected, we saw conserved 
Tyr355 and Lys320 (in red, HsLOX numbering system) that form the LTQ cofactor. 
Second, there are only two highly conserved His residues, His294 and His296, while 
typical amine oxidase usually has 3 conserved His. There are also several other conserved 
residues such as two Cys, two Asp, and a Gln. Previous investigation8 suggested that these 
Cys might be involved in disulfide cross-links that play crucial roles in stabilizing LOX 
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that was shown to be most active at, surprisingly, 55 °C,1e much higher than physiological 
temperature. The puzzle is then the roles of the Asp and Gln that might also be involved 
in catalysis and copper binding, and we proposed to use mutagenesis and spectroscopic 
experiments to answer these questions.  
6.3.2 Expression and biochemical characterization of lysyl oxidase. 
LOX contain a peptide leader that is cleaved during the maturation of the protein in 
vivo. It was proposed that,9 after translation, the leader peptide is N-glycosylated to allow 
folding of the protein and formation of LTQ cofactor as well as the copper center. The pro-
protein is then transported to extracellular space and the leader cleaved by peptidase, 
leaving behind the active mature protein. 
To begin with, we tried to express the final mature version of several LOX proteins: 
human LOX and LOXL1, and a bacteria LOX homologue from Enhygromyxa salina 
(NCBI accession ID: KIG17313.1), a marine myxobacteria. However, heterologous 
expression of these genes in E. coli failed to give active proteins with the refolding 
protocols described previously.10 This is probably because E. coli lacks the machinery 
necessary for the maturation of these proteins. We then tried a drosophila analogue of 
human LOX, the Drosophila melanogaster LOXL1 (DmLOXL1, NCBI accession ID: 
NP_524607.1) that can be expressed in a native drosophila S2 expression system as 
described previously.11  DmLOXL1 contains an N-terminal signal peptide domain and a 
C-terminal catalytic domain that shares high homology to the human lysyl oxidase (~50% 
to all LOX and LOX-like proteins) and contains all the top conserved residues. It is thus 
a good model for the human homologues. 
DmLOXL1 was successfully expressed in S2 cells and can be readily purified into 
homogeneity. The open reading frame of Dmloxl-1 encodes a protein with an estimated 
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molecular mass of 45.2 kDa (with tags for cloning and purification), a bit smaller than the 
MS results, 45.5kDa, Figure 6.4A. This discrepancy might be due to protein glycosylation, 
which is predicted by the NetNGlyc program, Figure 6.4B, and was seen in the X-ray 
structure of TPQ-containing LOX from Pichia pastoris6 and suggested in human 
LOXL2.12 The details of the possible glycosylation patterns need to be further verified by 
digestion/MS fingerprint experiments. 
Mature LOX contains the lysine-tyrosine quinone cofactor and a copper center. 
Purified and reconstituted DmLOXL1 showed a light pink color, with the UV-Vis 
spectrum showing a broad shoulder at ~500-520 nm, Figure 6.4C. After adding 
phenylhydrazine that forms hydrazone with the quinone cofactor, the color turned into 
yellow, with a stronger absorption peak at ~450 nm, Figure 6.4C.  
The activity of DmLOXL1 was examined by using AmplexRed fluorescent assay that 
detects the H2O2 formed during the oxidation reaction. The specific activity of DmLOX1 
was determined to be ~ 1.4 μmol/mg protein/min at 37 °C using cadaverine as the 
substrate, Figure 6.4D, E, which is ~10-fold higher than the previous reported value (115.7 
pmol/μg protein/min).11 
6.3.3 Spectroscopic investigation. 
Since LOX contain a paramagnetic mononuclear Cu2+ center, we investigated the EPR 
spectra of this protein. Shown in Figure 6.5A is the CW-EPR spectrum of reconstituted 
DmLOXL1. The spectrum contains two species, with g values [2.284, 2.060, 2.060] and 
[2.325, 2.061, 2.061], respectively. Both signals have large hyperfine coupling constant in 
parallel region, 482 and 463 MHz, typical of type II copper center. However, the intensity 
of the signal is weak, corresponding to a spin count of ~0.1 Cu2+/protein, indicating that 
the copper incorporation is not efficient in the protein. 
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We then performed electron spin echo envelope modulation (ESEEM) experiments, to 
investigate the His residues near the copper center, and compared the results to 
nitrosocyanin from Nitrosomonas europaea, another type II copper protein with a known 
structure in which the copper center is ligated with 2 His, 1 Cys and 1 Asp (Figure 6.6A).13 
We chose nitrosocyanin as a comparison since it is also a copper protein with a unique 
pink color. X-band (9 GHz) 2-pulse and 3-pulse ESEEM spectra of DmLOXL1 were 
recorded at g⊥ direction (Figure 6.5B), and the results are shown in Figure 6.5C, D. In 
nitrogen region there are mainly four signals. The first three, 0.5 MHz, 1.1 MHz and 1.6 
MHz, all < 2 MHz, are close to pure nuclear quadrupole resonance at near exact 
cancellation limit (A≈2ω). At this condition, the nuclear transition frequencies in ms=1/2 
manifold are given as follow: 
ν+= e2Qq/h *3(1+η)/4; ν-= e2Qq/h *3(1-η)/4; ν0= e2Qq/h *η/2 
where e2Qq/h is the nuclear quadrupole coupling constant and η is the asymmetry factor 
ranging from zero for pure axial symmetry to one for full rhombic. The e2Qq/h and η for 
DmLOXL1 are thus estimated to be 1.8 MHz and 0.56, respectively. There is also a signal 
at 3.8 MHz which we assigned to the double quantum transition of the 14N in the ms=-1/2 
manifold, corresponding to an aiso~1.9 MHz. Similar patterns were also seen with 
nitrosocyanin spectra, Figure 6.6D, F, with frequencies of 0.4 MHz, 0.8 MHz and 1.5 MHz. 
However, nitrosocyanin has more signals at ~3-4 MHz region, possibly from the double 
quantum transitions of the two remote nitrogens on His residues and the combinations 
of peaks at lower frequency region. For nitrosocyanin, we also obtained the 2-pulse and 
3-pulse ESEEM specta at g∥ direction, shown in Figure 6.6C, E. Spectra recorded at 
parallel orientation are more closely to the exact cancellation limit, as seen in the 
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HYSCORE spectrum described below. The three frequencies <2 MHz are 0.6 MHz, 0.9 
MHz and 1.5 MHz, and e2Qq/h and η are estimated to be 1.6 MHz and 0.75, respectively. 
For comparison, the e2Qq/h and η of a few other copper amine oxidases are listed in Table 
1. The relative large η for DmLOXL1 is consistent with values found before, as does e2Qq/h.  
We then obtained the HYSCORE spectra for both proteins, Figure 6.7 A-F. Shown in 
Figure 6.7A is the HYSCORE spectra for DmLOXL1. The cross peaks at (1.6, 4.0 MHz) are 
tentatively assigned to the two double quantum transition (DQα-DQβ) from 14Nδ in the 
His ligand. Similar peaks were also present in the HYSCORE spectra of nitrosocyanin 
sample, also at (1.6, 3.7 MHz), Figure 6.7B. In perpendicular orientation, nitrosocyanin 
also contains a cross peak at (3.0 MHz, 4.2 MHz), Figure 6.7B, with smaller hyperfine 
coupling but larger quadrupole interaction.  These peaks are possibly due to the double 
quantum transition from the protein backbone nitrogens.14 Such a signal is not present 
(or much weaker) in DmLOXL1 samples, or in the parallel orientation (B=287 mT) of 
nitrosocyanin spectrum, Figure 6.7C. Interestingly, as shown in Figure 6.7C, the two His 
ligands at this orientation are more separated, with double quantum transition cross-
peaks at (1.5, 3.1 MHz) and (1.4, 3.8 MHz) respectively. As mentioned above, the latter 
have a larger hyperfine coupling that are more close to cancellation frequency (aiso~1.7 
MHz~2ω(14N) = 1.76 MHz at 287 mT), and cross peaks can also be seen in the second 
quadrant (-, +), at (0.85 MHz, 3.8 MHz). Notably, with nitrosocyanin, the proton signal 
intensity is much larger in parallel orientation and also has a much smaller hyperfine 
coupling, (~0, 0.5, 2.2 MHz) than perpendicular orientation (0.6, 1.2, 4.2 MHz; Figure 
6.7C), while the proton signal intensity in DmLOXL1 is large at perpendicular orientation, 
indicating the presence of more water molecular nearby. Isotope labeling experiments 
may be necessary to give a better idea of the coordination environment of lysyl oxidase. 
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6.4 Conclusion 
The enzyme lysyl oxidase is an important contributing factor for cancer metastasis, and 
thus is of great interest as a drug target. In this study, we have expressed and purified the 
lysyl oxidase from drosophila, which has a catalytic domain that is highly homologous to 
the human lysyl oxidase. We have assayed the enzyme kinetics of drosophila lysyl oxidase, 
and also used EPR techniques to investigate the copper coordination sites of this enzyme. 
Our results are of interest since it provides insights into the structure and mechanism of 
this important amine oxidase for the first time. 
  
6.5 Material and Methods 
6.5.1 Expression and purification of DmLOXL1. 
The plasmid containing DmLOXL1 was a kind gift from Dr. Csiszar’s lab. The 
transfection and protein expression protocols were basically as described previously,15 but 
modified to use a Ni-NTA affinity chromatography. Briefly, the plasmid was co-
precipitated with a plasmid containing a hygromycin resistance marker using calcium 
phosphate. Drosophila S2 cells in complete medium were exposed to the precipitate for 
24 h, then transferred to fresh medium with 500 µg/ml hygromycin. The cells were 
cultured until stable transfected cells began to grow. For protein expression, recombinant 
cells were grown to 5×106 cell/ml in shake-flasks at 25 °C and induced by 0.5 mM copper 
sulfate. The cells were cultured for 2 more days before being removed from the medium 
by centrifugation. The medium was then diluted with equal volume of water and 120 g/L 
urea. Ni-NTA resin was added to the medium, and the suspension was stirred for 60 min 
at 4 °C. The resin was collected by centrifugation, washed with TBS-2M urea (TBS: 50 
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mM Tris/HCl, 150 mM NaCl, pH=7.5), and then eluted with TBS-2M urea containing 250 
mM imidazole. Purified protein was dialyzed against TBS-2M urea containing 10 mM 
2,2’-bipyridine for 1 day to remove all metal ions, then against TBS-2M urea containing 
0.5 mM CuSO4 for 2 days for copper incorporation, then against TBS-2 M urea containing 
10 mM EDTA to remove any adventitious Cu2+, and finally against TBS-2M urea buffer to 
remove EDTA. 
6.5.2 Activity assays of lysyl oxidase. 
The activity of lysyl oxidase was quantified with the AmplexRed fluorescent assay kit 
(Molecular Probes) to monitor the H2O2 formed during the oxidation according to the 
AmplexRed kit manual. 0.5 µg of recombinant DmLOXL1 in 100 µL TBS-2M urea was 
incubated with 10 mM cadaverine and the reaction was monitored over a period of 3 h. A 
series of H2O2 solutions (1 µM to 100 nM) were used to plot the standard curve and the 
specific activities of DmLOXL1 were calculated by comparing to the standard curve.  
6.5.3 CW- and pulsed EPR of lysyl oxidase. 
2000 µL of DmLOXL1 containing 20% glycerol was transferred to the EPR sample tube. 
CW-EPR experiments were performed at X-band (9 GHz) on a Varian E-122 spectrometer 
with Air Products helium cryostat. Typical parameters were as follow: temperature, 30K; 
power: 1 mW; modulation amplitude, 0.5 mT; field sweep, 300±50 mT. Pulsed-EPR 
experiments were performed on a Bruker ELEXSYS E-580-10 FT-EPR spectrometer with 
an Oxford CF935 cryostat. Typical parameters are as follow: frequency, 9.62 GHz; 
temperature, 30 K; power, 0.002 mW. 2-pulse ESEEM used a pulse sequence π/2-τ-π-τ-
echo. 3 pulse ESEEM used a pulse sequence π/2-τ-π/2-T-π/2-τ+T-echo with 10 pieces of 
τ (τ0=104 ns, 16 ns steps). HYSCORE experiments used a pulse sequence π/2-τ-π/2-t1-π-
t2-π/2-τ-echo with τ0=136 ns and 256 points for both t1 and t2. π/2 pulse =16 ns in all 
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pulsed experiments. Time domain pulsed spectra data were baseline corrected with a 
third order polynomial, Hamming window function multiplied, followed by zero filling 
and Fourier transformation by using Matlab (R2014a) and easyspin (5.0.22).16  
 
6.6 Figures and Tables 
 
 
 
Figure 6.1 Lysyl oxidase activates pre-osteoclasts that differentiate into active 
osteoclasts, and inhibits osteoblasts. The net result is bone lesion that creates micro-
environments for cancer metastasis. 
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Figure 6.2 Biogenesis of lysyl tyrosylquinone (LTQ), top; and a proposed mechanism 
of lysyl oxidase, bottom. 
 
 
 
 
Figure 6.3 (A) Domain architectures of LOX and LOX-like proteins. (B) Scorecons 
analysis showing top 15 conserved residues in the catalytic domain of human LOX. 
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Figure 6.4 Biochemical characterization of DmLOXL1. (A) MALDI-TOF of purified 
DmLOXL1. (B) Possible glycosylation sites of DmLOXL1 predicted by NetNGlyc 1.0 (C) 
UV-Vis spectra shows the adduct between DmLOXL1 with phenylhydrazine. (D) 
AmplexRed assay standard curve with different concentration of H2O2. (E) Activity of 
DmLOXL1 and background controls. 
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Figure 6.5 CW-and pulsed-EPR spectra of DmLOXL1. (A) CW-EPR showing two signals 
observed in DmLOXL1 sample. (B) Full absorption spectrum of DmLOXL1. The arrow 
indicated the position where pulsed experiments were performed. (C) 2-pulse ESEEM 
spectrum of DmLOXL1 at g⊥. (D) 3-pulse ESEEM spectrum of DmLOXL1 at g⊥. τ=104 ns 
for 3-pulse experiments. 
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Figure 6.6 Pulsed-EPR spectra of nitrosocyanin from Nitrosomonas europaea. (A) X-
ray of nitrosocyanin showing the coordination sphere of copper. (B) Full absorption 
spectrum of nitrosocyanin. The arrow indicated the position where pulsed experiments 
were performed. (C) 2-pulse ESEEM spectrum of nitrosocyanin at g∥. (D) 2-pulse ESEEM 
spectrum of nitrosocyanin at g⊥. (E) 3-pulse ESEEM spectrum of nitrosocyanin at g∥. (F) 
3-pulse ESEEM spectrum of nitrosocyanin at g⊥. τ=104 ns for 3-pulse experiments. 
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Figure 6.7 HYSCORE spectra for DmLOXL1 and nitrosocyanin. (A) HYSCORE spectrum 
of DmLOXL1 at g⊥ (333 mT). (B) HYSCORE spectrum of nitrosocyanin at g⊥ (333 mT). (C) 
HYSCORE spectrum of nitrosocyanin at g∥ (287 mT). τ=136 ns in all cases. 
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Table 6.1 14N hyperfine coupling and nuclear quadrupole coupling parameters for 
several copper enzymes with His ligands. 
Enzyme 
ESEEM frequencies 
 (MHz) 
e2Qq/h  
(MHz) 
η 
aiso  
(MHz) 
ref 
dopamine β-hydroxylase 0.7, 0.7, 1.4 1.44 0.98 1.75 [17] 
conalbumine 0.7, 0.8, 1.5 1.53 0.91  [18] 
laccase 0.59, 0.8, 1.48 1.52 0.89  [19] 
ascorbate oxidase 0.61, 0.89, 1.54 1.56 0.83  [20] 
galactose oxidase 0.55, 1.0, 1.53 1.70 0.6 1.8 [21] 
phenylalanine hydroxylase 0.55, 1.00, 1.55 1.68 0.55 2.0 [22] 
amine oxidase 0.45, 1.1, 1.55 1.73 0.48 2.3 [23] 
DmLOXL1 0.5, 1.1, 1.6 1.8 0.56 1.9 This study 
nitrosocyanin 0.6, 0.9, 1.5 1.6 0.75 1.6, 1.9 This study 
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